| Excerpt | Reference |
|---|
| "Type 1 diabetes is considered to be a chronic autoimmune disease characterized by gradual beta-cell destruction mediated by autoreactive T-lymphocytes during an asymptomatic prediabetic phase of varying duration." | ( Knip, M, 1992) |
| "Type 1 diabetes is not associated with decreased leucine clearance." | ( Biolo, G; Inchiostro, S; Piccoli, A; Saggin, L; Tessari, P; Tiengo, A, 1992) |
| "Patients with type 1 diabetes are usually given insulin subcutaneously, but this does not mimic the physiological route of pancreatic insulin release, which may be better achieved with intraperitoneal insulin." | ( Alberti, KG; Home, PD; Monti, LD; Piatti, PM; Tomson, C, 1992) |
| "Type 1 diabetes mellitus is associated with an increase in total exchangeable body sodium." | ( Greene, SA; Howey, J; O'Hagan, M, 1991) |
| "Type 1 diabetes is associated with antibodies that immunoprecipitate a 64-kD islet cell membrane protein from detergent extracts of pancreatic islets." | ( Champagne, P; Christie, MR; Daneman, D; Delovitch, TL; Vohra, G, 1990) |
| "Patients with type 1 diabetes are characterized by an average 40% reduction in the insulin sensitivity." | ( Koivisto, VA; Yki-Järvinen, H, 1990) |
| "Type 1 diabetes is said to be extremely rare in children in India, where diabetes treated with insulin may be due to chronic pancreatic disease or malnutrition." | ( Beverley, DW; Bodansky, HJ; Bottazzo, GF; Gelsthorpe, K; Haigh, D; Saunders, A, 1987) |
| "IDDM is characterized by progressive beta-cell destruction which leads to complete insulin deficiency; at the time of diagnosis 80-90% of beta cells have been destroyed." | ( Aro, A; Virtanen, SM, 1994) |
| "In conclusion, IDDM is characterised by reduced FVC and FEV1, while a significant decrease in DLCO may be considered as selectively associated with renal disease." | ( Anichini, R; De Giorgio, LA; Fabbri, A; Innocenti, F; Pettinà, G; Seghieri, G; Tuci, S; Vannucci, F, 1994) |
| "IDDM is caused by an immune-mediated destruction of the insulin-producing beta cells." | ( Andersen, HU; Pociot, F; Reimers, JI, 1994) |
| "Two children with IDDM are described whose hyperglycemia, ketosis, and abdominal pain were the presenting features of H." | ( Copeland, KC; Gunn, SK; Sherman, LD; Vogiatzi, MG, 1996) |
| "1) IDDM is associated with increased intramuscular TG content." | ( Ebeling, P; Essén-Gustavsson, B; Koivisto, VA; Tuominen, JA, 1998) |
| "Type 1 diabetes mellitus is a disease caused by the autoimmune destruction of insulin-producing pancreatic beta-cells that takes place in genetically prodisposed individuals." | ( Carabba, B; Di Mario, U; Diaz-Horta, O; Dionisi, S; Dotta, F; Viglietta, V, 1997) |
| "Development of type 1 diabetes is known to be correlated with a shift from a Th2 status during benign insulitis to a Th1 status during destructive insulitis." | ( Kolb, H; Rothe, H, 1999) |
| "IDDM is a common disorder in the Western world and it is rising in incidence." | ( Sjöholm, A, 1998) |
| "Autoimmune diabetes is characterized by a chronic progressive inflammatory autoimmune reaction that ultimately causes the selective elimination of pancreatic beta cells." | ( Ho, A; Kägi, D; Mak, TW; Odermatt, B; Ohashi, PS; Zakarian, A, 1999) |
| "Type 1 diabetes is a major histocompatibility complex (MHC) class II-associated autoimmune disease mediated by beta-cell-specific T-cells and characterized by circulating autoantibodies to beta-cell molecules." | ( Ellerman, KE; Like, AA, 1999) |
| "Type 1 diabetes is based on autoimmunity, and its development is in part determined by environmental factors." | ( Jagla, A; Schrezenmeir, J, 2000) |
| "Vascular disease in type 1 diabetes is a complex and multifactorial process, which probably begins in childhood in association with the onset of diabetes." | ( Belch, JJ; Elhadd, TA; Greene, SA; Khan, F, 2000) |
| "Poorly controlled IDDM is associated with reversible renal resistance to AVP." | ( Baylis, PH; Frier, BM; Ishikawa, S; McKenna, K; Morris, AD; Newton, RW; Ryan, M; Saito, T; Thompson, CJ, 2000) |
| "Type 1 diabetes is associated with abnormalities of the growth hormone (GH)-IGF-I axis." | ( Bowes, SB; Carroll, PV; Christ, ER; Croos, P; Gowrie, I; Hovorka, R; Jackson, N; Russell-Jones, DL; Sönksen, PH; Umpleby, AM, 2000) |
| "Type 1 diabetes is considered to be a T-cell-mediated autoimmune disease in which insulin-producing beta-cells are destroyed." | ( Akerblom, HK; Ilonen, J; Knip, M; Paronen, J; Savilahti, E; Vaarala, O; Virtanen, SM, 2000) |
| "Type 1 diabetes is an autoimmune disease leading to extensive destruction of the pancreatic beta-cells." | ( Andersson, AK; Barbu, A; Eizirik, DL; Flodström, M; Hellerström, C; Holstad, M; Karlsson, E; Saldeen, J; Sandberg, JO; Sandler, S; Sternesjö, J; Strandell, E; Tillmar, L; Welsh, N, 2000) |
| "Type 1 diabetes is the result of a chronic inflammatory process that causes elimination of insulin-producing beta-cells, resulting in insulin deficiency and hyperglycemia." | ( Berne, C; Björk, E; Karlsson, FA; Kullin, M; Li, Z; Ma, JY; Schölin, A; Zhao, L, 2000) |
| "Type 1 diabetes is a common multi-factorial disease." | ( Dahl-Jørgensen, K; Joner, G; Nicol-Smith, L; Rønningen, KS; Søvik, O; Torjesen, PA; Undlien, DE, 2000) |
| "Type 1 diabetes mellitus is an autoimmune disease in which the presence of different autoantigens can often be found." | ( Hilgertová, J; Límanová, Z; Prázný, M; Skrha, J, 1999) |
| "Children with type 1 diabetes are frequently difficult to manage during times of gastroenteritis or poor oral intake of carbohydrates because of mild or impending hypoglycemia." | ( Haymond, MW; Schreiner, B, 2001) |
| "Type 1 diabetes is associated with a high risk of coronary heart disease (CHD), despite the absence of dyslipidemia." | ( Elkeles, RS; McColl, AJ; Richmond, W; Rubens, MB; Schachter, M; Valabhji, J, 2001) |
| "Type 1 diabetes mellitus is a chronic disorder that presumably results from an autoimmune destruction of the insulin-producing pancreatic beta cells." | ( Atkinson, M; Brod, SA; Brosnan, PG; Hardin, DS; Lavis, VR; Nguyen, M; Orlander, PR; Riley, WJ, 2001) |
| "Type 1 diabetes is associated with coronary heart disease (CHD) and coronary artery calcification (CAC), a measure of subclinical CHD." | ( Cheng, S; Eckel, RH; Ehrlich, J; Erlich, HA; Fijal, BA; Grow, MA; Hokanson, JE; Hung, C; Rewers, M; Snell-Bergeon, JK, 2002) |
| "Type 1 diabetes is a chronic progressive autoimmune disease characterized by mononuclear cell infiltration, dominated by interleukin-12 (IL-12)-dependent Th1 cells, of the pancreatic islets, with subsequent destruction of insulin-producing beta-cells." | ( Adorini, L; Giarratana, N; Gregori, S; Smiroldo, S; Uskokovic, M, 2002) |
| "Patients with type 1 diabetes are identified after the onset of the disease, when beta cell destruction is almost complete." | ( Ayuso, E; Bosch, F; Casellas, A; Costa, C; Devedjian, JC; George, M, 2002) |
| "Autoimmune diabetes is one of the most common chronic diseases in the world." | ( Datta, M; Gupta, V; Mani, MK; Sanjeevi, CB; Shtauvere-Brameus, A, 2002) |
| "Type 1 diabetes is associated with a high incidence of coronary heart disease (CHD) despite paradoxically normal or high high-density lipoprotein (HDL) cholesterol concentrations." | ( Donovan, J; Elkeles, RS; McColl, AJ; Richmond, W; Schachter, M; Valabhji, J, 2002) |
| "Type 1 diabetes mellitus is a chronic autoimmune disease caused by the pathogenic action of T lymphocytes on insulin-producing beta cells." | ( Auger, JA; Bluestone, JA; Donaldson, D; Gitelman, SE; Hagopian, W; Harlan, DM; Herold, KC; Poumian-Ruiz, E; Taylor, L; Xu, D; Zivin, RA, 2002) |
| "Type 1 diabetes is associated with lower levels of FXIIa despite a greater prevalence of atherosclerosis." | ( Colhoun, HM; Fuller, JH; Humphries, SE; Norman Chan, N; Rubens, MB; Zito, F, 2002) |
| "Type 1 diabetes is considered to be an autoimmune disease in which T lymphocytes infiltrate the islets of pancreas and destroy the insulin producing beta cell population." | ( Akerblom, HK; Hyöty, H; Ilonen, J; Knip, M; Vaarala, O, 2002) |
| "Human type 1 diabetes is associated with defects in the hematopoietic stem cells." | ( Guo, Z; Hering, B; Heuss, N; Kirchhof, N; Levay-Young, B; Sozen, H; Sutherland, DE; Wu, T, 2002) |
| "Adolescents with IDDM are characterised by morning hypoinsulinaemia and high circulating IGFBP-1 concentrations, which may contribute to insulin resistance and impaired metabolic control during puberty." | ( Knip, M; Riihimaa, PH; Ruokonen, A; Tapanainen, P, 2002) |
| "The incidence of Type 1 diabetes is lower in Iceland than in the other 4 Nordic Countries." | ( Birgisdottir, BE; Harris, DP; Hill, JP; Thorsdottir, I, 2002) |
| "Immune mediated type 1 diabetes is the most frequent form of childhood diabetes while type 2 and other forms are more rare in childhood in the Caucasian population." | ( Hermann, R; Makovi, H; Soltész, G, 2002) |
| "Type 1 diabetes is associated with impaired responsiveness to NO and with an impairment in ACh-stimulated NO release." | ( Chan, NN; Colhoun, HM; Vallance, P, 2003) |
| "Type 1 diabetes is an autoimmune disorder caused by cellular-mediated destruction of insulin-producing pancreatic beta cells in the islets of Langerhans." | ( Brinkmann, V; Chen, M; Ellett, JD; Fialkow, LB; Lynch, KR; Nadler, JL; Wu, R; Yang, Z, 2003) |
| "Type 1 diabetes is an autoimmune disease with a Th1 phenotype in which insulin-producing beta-cells in the pancreas are destroyed." | ( Aud, D; Erlich, HA; Grupe, A; Lazzeroni, LC; Mirel, DB; Noble, JA; Peltz, G; Reynolds, R; Valdes, AM; White, AM, 2003) |
| "beta-cell death in type 1 diabetes is due predominantly to autoimmunity." | ( Donath, MY; Maedler, K; Mandrup-Poulsen, T; Størling, J, 2003) |
| "Type 1 diabetes mellitus is associated with high levels of premature morbidity and mortality." | ( Bain, SC; Barnett, AH; Dyer, PH; Gill, GV; Jones, AF; Jones, KE; Murphy, M; Smyth, C, 2003) |
| "Type 1 diabetes is associated with a number of diabetes-related complications which may be minimized by maintaining good long-term metabolic control." | ( Ratner, R, 2003) |
| "Type 1 diabetes mellitus is one of the most common chronic diseases of childhood." | ( Deepa, R; Mohan, V; Radha, V; Vimaleswaran, KS, 2003) |
| "Type 1 diabetes is an autoimmune disease with an inflammatory process directed against the beta cells in pancreas." | ( Ernerudh, J; Karlsson Faresjö, MG; Ludvigsson, J, 2004) |
| "Type 1 diabetes is a rare but serious complication of interferon therapy." | ( Peters, T; Rasenack, J; Reincke, M; Schories, M, 2004) |
| "Type 1 diabetes is an immune-mediated disease with pancreatic infiltration and subsequent beta cell destruction." | ( Gornitzka, G; Hansner, T; Kauer, M; Kolb, H; Martin, S, 2004) |
| "Type 1 diabetes mellitus is a multifactorial autoimmune disease characterized by destruction of insulin producing pancreatic beta cells that results in insulin deficiency and fasting hyperglycemia." | ( Dotta, F; Vendrame, F; Zappaterreno, A, 2004) |
| "Type 1 diabetes is one of the most frequent chronic diseases in childhood." | ( Brink, SJ; Chiarelli, FG, 2004) |
| "Type 1 diabetes mellitus is caused by autoimmune pancreatic beta cell destruction, and the destructive process involves several molecular mechanisms including oxygen-reactive species." | ( Irie, J; Oikawa, Y; Saruta, T; Shigihara, T; Shimada, A, 2004) |
| "Childhood type 1 diabetes is defined by autoimmunity and insulinopenia." | ( Drăghici, C; Enache, A; Roşca, A; Roşu, M; Serban, V; Sima, A; Vlad, A, 2004) |
| "While type 1 diabetes is the most frequent form of diabetes among Caucasian children, measurement of diabetes autoantibodies and C peptide is necessary to better define the types of diabetes in youth." | ( Drăghici, C; Enache, A; Roşca, A; Roşu, M; Serban, V; Sima, A; Vlad, A, 2004) |
| "As early Type 1 diabetes is characterized by a relative glomerular hyperfiltration, increased renal clearance could contribute to decreased levels of homocysteine as observed in Type 1 diabetes mellitus." | ( Blom, H; Smits, P; Veldman, BA; Vervoort, G, 2005) |
| "Type 1 diabetes is a prevalent chronic disease in childhood with the commonest single cause of death being cerebral oedema in the context of diabetic ketoacidosis (DKA)." | ( Cameron, FJ; Inder, TE; Kean, MJ; Neil, JJ; Wellard, RM; Werther, GA, 2005) |
| "Type 1 diabetes mellitus is a T-cell-mediated autoimmune disease that leads to a major loss of insulin-secreting beta cells." | ( Bach, JF; Berrie, E; Bird, P; Candon, S; Chatenoud, L; Crenier, L; De Block, C; De Pauw, P; Frewin, M; Goldman, M; Gorus, F; Hale, G; Kaufman, L; Keymeulen, B; Mathieu, C; Pierard, D; Pipeleers, D; Rebello, P; Schandene, L; Seigneurin, JM; Vandemeulebroucke, E; Waldmann, H; Walter, M; Weets, I; Ziegler, AG, 2005) |
| "Autoimmune diabetes is a complex, multifactorial disease caused by the interaction of genetic and environmental factors." | ( Caputo, M; Cedola, N; Cerrone, GE; Frechtel, GD; Gonzalez, C; Lopez, AP; Mazza, C; Puchulu, FM; Targovnik, HM, 2005) |
| "Incidence of type 1 diabetes is considered to be low in adults, but no study has been performed in Mediterranean countries." | ( Bruno, G; Cavallo-Perin, P; Cerutti, F; Merletti, F; Novelli, G; Pagano, G; Pinach, S; Rivetti, M; Runzo, C; Trovati, M, 2005) |
| "Type 1 diabetes is a common chronic disease in childhood, and the outcome of environmental, genetic and immunologic interactions." | ( Abdella, N; Al-Sheikh, N; Alsaeid, M; Gomez, JE; Moussa, MA; Refai, TM, 2005) |
| "Type 1 diabetes is a chronic disease that can lead to many serious complications if not properly managed." | ( Lisle, DK; Trojian, TH, 2006) |
| "Management of type 1 diabetes is best undertaken in the context of a multidisciplinary health team and requires continuing attention to many aspects, including insulin administration, blood glucose monitoring, meal planning, and screening for comorbid conditions and diabetes-related complications." | ( Daneman, D, 2006) |
| "Adult type 1 diabetes mellitus is associated with a decreased risk of goiter and nodules and an increased risk of thyroid autoimmunity." | ( John, U; Kerner, W; Krohn, U; Lüdemann, J; Völzke, H; Wallaschofski, H, 2007) |
| "Type 1 diabetes is an immuno-inflammatory condition which increases the risk of cardiovascular disease, particularly in young adults." | ( Barton, M; Frank, B; Hofmann-Lehmann, R; Nett, PC; Terracciano, LM; Tornillo, L; Traupe, T, 2007) |
| "Type 1 diabetes is a metabolic disorder caused by loss of insulin-producing pancreatic beta-cells." | ( Han, J; Jun, HS; Kwon, H; Lee, HH; Shin, S; Yoon, JW, 2007) |
| "Type 1 diabetes is characterized by T cell-mediated autoimmune destruction of pancreatic beta cells." | ( Boggi, U; Censini, S; Covacci, A; Del Prato, S; Dionisi, S; Dotta, F; Elliott, JF; Marchetti, P; Marselli, L; Masini, M; Mosca, F; Muda, AO; Rappuoli, R; Roep, BO; van Halteren, AG, 2007) |
| "Fulminant type 1 diabetes is known to have IDDM-resistant HLA DR2 with similar frequency of non-T1D subjects." | ( Hara, K; Kishi, M; Kotani, R; Kurohara, M; Moriyama, H; Nagata, M; Yasuda, H; Yokono, K, 2007) |
| "Type 1 diabetes mellitus is an autoimmune disease characterized by progressive destruction of pancreatic beta cells by genetic and environmental factors which leads to an absolute dependence of insulin for survival and maintenance of health." | ( Eguchi, K; Ichinose, K; Kawasaki, E, 2007) |
| "The incidence of type 1 diabetes is increasing world wide, especially in younger children." | ( Aggarwal, A; Bhatia, E, 2007) |
| "Type 1 diabetes is associated with the presence of inflammation, which in turn affects parameters used to assess the vitamin A status." | ( Espe, K; Galler, A; Kiess, W; Raila, J; Schweigert, FJ, 2007) |
| "Autoimmune diabetes is predominated by a T helper 1 (Th1) response at the expense of an impaired Th2 response." | ( Haskins, K; He, J, 2008) |
| "Type 1 diabetes mellitus is associated with a number of disorders of skeletal health, conditions that rely, in part, on dynamic bone formation." | ( Bunn, RC; Cockrell, GE; Coleman, HN; Fowlkes, JL; Liu, L; Lumpkin, CK; Perrien, DS; Thrailkill, KM; Wahl, EC, 2008) |
| "Type 1 diabetes is associated with an increased risk of vascular complications." | ( Chaturvedi, N; Fuller, JH; Pickup, JC; Soedamah-Muthu, SS, 2008) |
| "Type 1 diabetes is a chronic disease characterized by progressive destruction of the pancreatic beta cells, what leads to insulin deficiency and hyperglycemia." | ( Milech, A; Oliveira, JE; Rodacki, M, 2008) |
| "Type 1 diabetes is an autoimmune disease characterized by inflammation of pancreatic islets and destruction of beta cells by the immune system." | ( Amirshahrokhi, K; Dehpour, AR; Ghazi-Khansari, M; Hadjati, J; Sotoudeh, M, 2008) |
| "Type 1 diabetes is caused by autoimmune destruction of insulin-producing cells in the pancreas." | ( Bagley, J; Iacomini, J; Tian, C, 2008) |
| "Type 1 diabetes mellitus is associated with acute and long-term complications, to which pre- and postprandial hyperglycemia are independent contributors." | ( Neira, CP; Velásquez-Mieyer, PA, 2008) |
| "Patients with type 1 diabetes mellitus are more susceptible than healthy individuals to exercise-induced oxidative stress and vascular endothelial dysfunction, which has important implications for the progression of disease." | ( Ashton, T; Bailey, DM; Davies, B; Davison, GW; George, L; Jackson, SK; McEneny, J; Peters, JR; Young, IS, 2008) |
| "The development of type 1 diabetes is influenced by both genetic and environmental factors." | ( Cooke, A, 2009) |
| "Type 1 diabetes is recognised to include an element of insulin resistance." | ( Narendran, P; Pang, TT, 2008) |
| "Type 1 diabetes mellitus is considered a common form of diabetes mellitus in young people." | ( Gowda, S; Jali, MV; Jali, SM; Kambar, S; Patil, VD, 2009) |
| "Type 1 diabetes is diagnosed when the patient's endogenous insulin secretion decreases to a level which results in hyperglycemia." | ( Palmer, JP, 2009) |
| "Type 1 diabetes mellitus is caused by immune-mediated destruction of pancreatic beta-cells leading to insulin deficiency, impaired intermediary metabolism, and elevated blood glucose concentrations." | ( Harlan, DM; Harrison, VS; Koczwara, K; Lee, J; Pechhold, K; Walker, G; Zhu, X, 2009) |
| "Type 1 diabetes is associated with premature arterial disease." | ( Agarwal, SC; Aldibbiat, A; Home, PD; Mitchell, G; Oates, C; Razvi, S; Shaw, JA; Sibal, L; Weaver, JU, 2009) |
| "Type 1 diabetes is associated with a unique form of cardiomyopathy that is present without atherosclerosis." | ( Baliga, R; Bauer, JA; Giannone, PJ; Han, B; Huang, H, 2009) |
| "Because type 1 diabetes is caused by T cell-mediated destruction of beta cells and severe islet inflammation, we hypothesized that berberine could ameliorate type 1 diabetes through its immune regulation properties." | ( Cui, G; Ge, B; Gong, Z; Qin, X; Zang, YQ; Zhang, Y, 2009) |
| "Type 1 diabetes is a chronic autoimmune disease in which pancreatic beta cells are selectively destroyed." | ( Bretzel, RG; Elias, D; Fischer, B; Linn, T, 2010) |
| "Since type 1 diabetes is associated with vascular damage, we hypothesized high CEC numbers in this patient population." | ( Akalin, S; Asicioglu, E; Deyneli, O; Gogas Yavuz, D; Koc, M; Ozben, B; Yazici, D, 2010) |
| "Type 1 diabetes is a common and very serious disease." | ( Ludvigsson, J, 2010) |
| "Type 1 diabetes is responsible for approximately 10% of the whole diabetic morbidity." | ( Gero, L, 2010) |
| "The incidence of type 1 diabetes is increasing in Denmark as well as the rest of the world." | ( Grauslund, J, 2010) |
| "Type 1 diabetes is associated with elevated levels of blood PAI-1 and cardiovascular disease (CVD) incidence." | ( Jain, SK; Velusamy, T, 2011) |
| "Type 1 diabetes is a complex disease caused by multiple genetic and environmental factors." | ( Elfving, M; Ivarsson, SA; Jönsson, BA; Lindh, C; Olofsson, P; Rignell-Hydbom, A; Rylander, L, 2010) |
| "Autoimmune diabetes is a particular case in which debulking is ineffective due to resistance of the effector cells to depletion by conventional immunosuppressive therapies." | ( Askenasy, EM; Askenasy, JJ; Askenasy, N, 2010) |
| "Women with type 1 diabetes are subfertile." | ( Fischer, B; Fischer, S; Navarrete Santos, A; Ramin, N; Schindler, M; Schmidt, T; Thieme, R, 2010) |
| "Type 1 diabetes is a chronic autoimmune disease characterized by a preclinical period of autoimmunity." | ( Norris, JM, 2010) |
| "Type 1 diabetes mellitus is a major endocrine disorder, affecting approximately 5% of the world's population." | ( Balderas, C; Barbas, C; García, A; González-Casado, I; Gracia-Bouthelier, R; Guerrero-Fernández, J; Ibañez, E; Rupérez, FJ; Señorans, J; Villaseñor, A, 2010) |
| "The pathogenesis of type 1 diabetes is connected with immune-mediated beta-cell destruction leading to insulin deficiency." | ( Fendler, W; Młynarski, W; Wegner, O; Wyka, K; Zmysłowska, A, 2010) |
| "Graves' disease and type 1 diabetes are often complicated, and the coincidental occurrence of these 2 diseases is known as autoimmune polyglandular syndrome type III." | ( Fujioka, T; Honda, M; Koyama, K; Matsuno, H; Ogawa, M; Shimokawa, K; Yoshizaki, T, 2010) |
| "Young adults with type 1 diabetes are reported to have a lower peak bone mass than healthy individuals, which could possibly lead to an increased fracture risk in the future." | ( Ballinari, P; Flück, CE; Janner, M; Mullis, PE, 2010) |
| "The autoimmunity of type 1 diabetes is associated with T-cell hyperactivity." | ( Damnjanovic, I; Jevtovic, T; Kocic, G; Kocic, R; Nikolic, G; Pavlovic, V; Saranac, LJ; Sokolovic, D; Stojanovic, S; Zivic, S, 2010) |
| "Type 1 diabetes is considered non-reversible at end-stage disease when there is no measurable insulin production." | ( Bonifacio, E; Lampasona, V; Maffi, P; Magistretti, P; Monti, L; Perseghin, G; Piemonti, L; Secchi, A, 2011) |
| "Type 1 diabetes mellitus is an auto-immune disease." | ( Dosi, RV; Tandon, N, 2010) |
| "Type 1 diabetes is a serious chronic disease in which the pancreatic islet beta cells are destroyed by autoimmunity specifically directed to intracellular autoantigens." | ( Larsson, HE; Lernmark, A, 2011) |
| "Type 1 diabetes is an autoimmune disorder resulting from lymphocyte-mediated destruction of insulin-producing β cells in pancreas." | ( Chuang, YP; Lin, YC; Sytwu, HK, 2011) |
| "Fulminant type 1 diabetes mellitus is a recently described presentation of diabetes mellitus that has been predominately reported in Japan and other Asian countries." | ( McCauley, RA; Wang, X, 2011) |
| "The hallmark of type 1 diabetes is autoimmune destruction of the insulin-producing β-cells of the pancreatic islets." | ( Benoist, C; Gaglia, J; Kohler, RH; Kulkarni, RN; Li, L; Liew, CW; Mathis, D; Reiner, T; Thurber, G; Upadhyay, R; Vinegoni, C; Weissleder, R, 2011) |
| "Type 1 diabetes mellitus is believed to be due to the autoimmune destruction of β-cells by T lymphocytes, but a single course of rituximab, a monoclonal anti-CD20 B lymphocyte Ab, can attenuate C-peptide loss over the first year of disease." | ( Asare, A; Bourcier, K; Dosch, HM; Herold, KC; Krause-Steinrauf, H; Lachin, JM; Liu, Z; McGee, P; Pescovitz, MD; Spain, LM, 2011) |
| "Type 1 diabetes is an autoimmune disease." | ( Bach, JF; Chatenoud, L, 2011) |
| "Fulminant type 1 diabetes is defined as a subtype of type 1 diabetes with a remarkably acute onset." | ( Hanafusa, T; Imagawa, A, 2011) |
| "Persons with type 1 diabetes are at high risk for kidney disease, but there are no interventions that have been proved to prevent impairment of the GFR in this population." | ( Cleary, PA; de Boer, IH; Lachin, JM; Molitch, ME; Steffes, MW; Sun, W; Zinman, B, 2011) |
| "Type 1 diabetes is associated with increased platelet reactivity." | ( Crea, F; Ghirlanda, G; Lanza, GA; Manto, A; Mollo, R; Navarese, EP; Pitocco, D; Rizzo, P; Scalone, G; Scavone, G; Zaccardi, F, 2012) |
| "Fulminant Type 1 diabetes is a subtype of Type 1 diabetes characterized by (1) abrupt onset of diabetes, (2) very short duration of hyperglycaemia with mildly elevated HbA(1c) (< 69 mmol/mol, 8." | ( Ahn, KJ; Choi, JH; Chung, HY; Hwang, YC; Jeong, IK; Kang, JH; Kim, EY; Kim, HS; Kim, SY; Lee, TY, 2012) |
| "Type 1 diabetes is an autoimmune disease characterized by T cell responses to β cell Ags, including insulin." | ( Antal, Z; Babad, J; Baker, JC; DiLorenzo, TP; Jarchum, I; Mukherjee, G; Santamaria, P; Sette, A; Sidney, J; Smith, C; Yang, Y, 2012) |
| "Type 1 diabetes is an autoimmune disease that gradually destructs insulin-producing beta cells." | ( Gupta, S, 2012) |
| "Type 1 diabetes is a T-cell-mediated autoimmune disease in which autoreactive CD8(+) T cells destroy the insulin-producing pancreatic beta cells." | ( Jansen, DT; Joosten, AM; Kleijwegt, FS; Laban, S; Nikolic, T; Roep, BO; Teeler, J, 2013) |
| "Type 1 diabetes is an insulin-resistant state, but it is less clear which tissues are affected." | ( Bergman, BC; Clement, TW; Eckel, RH; Howard, D; Maahs, DM; Perreault, L; Rewers, M; Schauer, IE; Snell-Bergeon, JK, 2013) |
| "Since type 1 diabetes is an immunologically mediated disease, immune intervention should alter the natural history of the disease." | ( Skyler, JS, 2013) |
| "Type 1 diabetes is caused by autoimmune-mediated β cell destruction leading to insulin deficiency." | ( Biason-Lauber, A; Boily, G; Böni-Schnetzler, M; Bouzakri, K; Brorsson, C; Bruggmann, R; Brunner, A; Carballido, JM; Cavelti-Weder, C; Cermak, JM; Donath, MY; Elliott, P; Ellis, JL; Eloranta, JJ; Fontana, A; Geier, A; Glaser, B; Hubbard, BP; Keller, C; Kerr-Conte, J; Knobel, U; Konrad, D; Leibowitz, G; Matter, CM; McBurney, MW; Meier, DT; Meyer-Böni, M; Patrignani, A; Pattou, F; Pociot, F; Regairaz, C; Rogler, G; Schlapbach, R; Sinclair, DA; Timper, K; Westphal, C; Zulewski, H, 2013) |
| "People with type 1 diabetes are at high risk of premature atherosclerosis." | ( Brunzell, JD; Cleary, PA; de Boer, IH; Hoofnagle, AN; Lachin, JM; Molitch, ME; Sachs, MC; Steffes, MW; Zinman, B, 2013) |
| "Type 1 diabetes is a disorder where slow destruction of pancreatic β-cells occurs through autoimmune mechanisms." | ( Farhy, LS; McCall, AL, 2013) |
| "Type 1 diabetes is a chronic immune-mediated disease resulting in destruction of insulin-producing β-cells." | ( Cohen, IR; Schloot, NC, 2013) |
| "Classically, type 1 diabetes is thought to proceed to absolute insulin deficiency." | ( Besser, RE; Brown, RJ; Hattersley, AT; Jones, AG; Knight, BA; McDonald, TJ; Oram, RA; Shields, BM, 2014) |
| "Type 1 diabetes is an endocrinologic disorder characterized by uncontrolled glucose regulation and oxidative stress." | ( Jung, JH; Kim, HS; Park, JH; Yang, JY, 2013) |
| "Type 1 diabetes is a chronic condition characterized by insufficient production of insulin, a hormone needed for proper control of blood glucose levels." | ( Schmidt, S, 2013) |
| "Type 1 diabetes is a common autoimmune disease that has genetic and environmental determinants." | ( Clarke, P; Cooper, JD; Downes, K; Dunger, DB; Ferreira, RC; Howson, JM; Jolley, J; Marcovecchio, ML; Nutland, S; Stevens, HE; Todd, JA; Walker, NM; Wallace, C, 2014) |
| "Type 1 diabetes is due to destruction of pancreatic β-cells." | ( Aikin, RA; Billestrup, N; Birkbak, N; Blaabjerg, L; Christensen, DP; Dahllöf, MS; Dinarello, CA; Fossati, G; Grunnet, LG; Gysemans, C; Lundh, M; Mandrup, S; Mandrup-Poulsen, T; Mascagni, P; Mathieu, C; Monzani, V; Noesgaard, D; Paraskevas, S; Piemonti, L; Schmidt, SF; Workman, CT, 2014) |
| "Individuals with type 1 diabetes mellitus are at high risk for the development of hypertension, contributing to cardiovascular complications." | ( Broedl, UC; Cherney, DZ; Fagan, N; Har, R; Johansen, OE; Perkins, BA; Soleymanlou, N; von Eynatten, M; Woerle, HJ, 2014) |
| "Type 1 diabetes is an organ-specific autoimmune disease, characterized by selective destruction of insulin-producing pancreatic β-cells by T-cell-mediated inflammation." | ( Herold, KC; Vudattu, NK, 2014) |
| "Type 1 diabetes is preceded by the appearance of islet autoantibodies." | ( Beyerlein, A; Bonifacio, E; Stumpp, C; Ziegler, AG, 2014) |
| "Autoimmune diabetes is characterized by the selective destruction of insulin-secreting β-cells that occurs during an inflammatory reaction in and around pancreatic islets of Langerhans." | ( Broniowska, KA; Corbett, JA; Oleson, BJ, 2014) |
| "Type 1 diabetes is an autoimmune disease that results from an inflammatory destruction of β-cells in islets." | ( Fu, Z; Gao, H; Hu, J; Sun, R; Wang, F; Wang, L; Wang, Y; Wang, Z; Yan, S; Yu, X; Zhao, W, 2015) |
| "Type 1 diabetes is caused by an aberrant response against pancreatic β cells." | ( Asadi, A; Cheung, AT; Dickie, P; Fujita, Y; Grassl, GA; Kieffer, TJ; Lam, AW; Mojibian, M; Tan, R, 2014) |
| "Type 1 diabetes is associated with subfertility in humans." | ( Bertschinger, A; Chi, M; Drury, A; Esakky, P; Moley, KH; Schoeller, EL, 2014) |
| "Type 1 diabetes is recognized as an autoimmune inflammatory disease and low grade inflammation is also observed in type 2 diabetic patients." | ( Abbasi, F; Asgarian-Omran, H; Ataie-Jafari, A; Bajouri, A; Larijani, B; Maleki, A; Meysamie, A; Nikbin, B; Nikmanesh, B; Qorbani, M; Roohi, A; Shafiey, N; Tabrizi, M, 2014) |
| "Axonal function in type 1 diabetes is maintained within normal limits in patients treated with continuous subcutaneous insulin infusion and not with multiple daily insulin injections." | ( Arnold, R; Kiernan, MC; Krishnan, AV; Kwai, N; Lin, CS; Poynten, AM, 2015) |
| "Type 1 diabetes is a multifactorial inflammatory disease that develops as a result of deregulated immune responses, causing progressive autoimmune destruction of insulin-producing beta cells of pancreas." | ( Haegeman, G; Nikolic, I; Saksida, T; Stojanovic, I; Stosic-Grujicic, S; Vujicic, M, 2014) |
| "Type 1 diabetes is a common chronic disease of childhood and one of the most difficult conditions to manage." | ( Chung, ST; Haymond, MW, 2015) |
| "Microalbuminuria in type 1 diabetes is the earliest manifestation of diabetic microangiopathy (nephropathy)." | ( Bertini, M; Costa, M; Fassari, AL; Messina, M; Romano, C; Tamburella, C, 2014) |
| "Type 1 diabetes is one of the most extensively studied autoimmune diseases, but the cellular and molecular mechanisms leading to T cell-mediated destruction of insulin-producing β cells are still not well understood." | ( Gourdie, R; Ignatowicz, L; Kraj, P; Kuczma, M; Wang, CY, 2015) |
| "Type 1 diabetes mellitus is associated with a high risk for bone fractures." | ( Bouvard, B; Chappard, D; Flatt, PR; Irwin, N; Mabilleau, G; Mansur, SA; Mieczkowska, A, 2015) |
| "Type 1 diabetes is associated with portal insulin deficiency and disturbances in the GH-IGF axis including low circulating IGF-I and GH hypersecretion." | ( Bang, P; Brorsson, AL; Carlsson-Skwirut, C; Ekström, K; Frystyk, J; Ma, Z; Pulkkinen, MA, 2015) |
| "Type 1 diabetes is caused by the destruction of insulin producing beta cells by the immune system." | ( Barbera Betancourt, A; Cooke, A; Emery, JL; Okkenhaug, K; Recino, A; Wallberg, M; Wong, FS, 2016) |
| "Type 1 diabetes mellitus is heterogeneous in many facets." | ( An, M; Bian, L; Bu, R; Cai, Y; Chen, H; Chen, Y; Cheng, J; Cheng, X; Cui, S; Dai, H; Dong, J; Fang, C; Fei, X; Fu, Q; Fu, Y; Gao, J; Gu, W; Gu, Y; Han, G; Han, X; He, W; Hu, J; Hu, Q; Ji, L; Jin, H; Jin, Y; Li, W; Li, Y; Liang, J; Liu, J; Lu, W; Ma, B; Ma, J; Miao, H; Qian, L; She, J; Shen, J; Shi, B; Shi, G; Shi, X; Shi, Y; Sun, Z; Tang, W; Wang, G; Wang, J; Wang, X; Wang, Z; Wu, C; Xie, Y; Xin, B; Xu, C; Xu, K; Xu, L; Xu, N; Xu, X; Yang, F; Yang, T; Yu, J; Yu, L; Yu, W; Zhang, M; Zhang, Q; Zhang, W; Zhang, Z; Zheng, S; Zheng, X; Zhong, S; Zhou, D; Zhou, H; Zhu, D; Zhu, Y, 2016) |
| "Patients with type 1 diabetes mellitus are associated with impairment in vitamin A metabolism." | ( Chang, FP; Chien, CY; Cho, CH; Lee, HS; Mao, WY; Shen, CN; Wu, RR; Yuan, TA, 2016) |
| "Many patients with type 1 diabetes are medicated with HMG-CoA reductase inhibitors, statins, in order to prevent vascular complications." | ( Bergen, K; Brismar, K; Tehrani, S, 2016) |
| "Type 1 diabetes is associated with osteopenia and increased fragility fractures, attributed to reduced bone formation." | ( Almeida, M; Ambrogini, E; Fowlkes, J; Han, L; Iyer, S; Manolagas, SC; Yavropoulou, M, 2017) |
| "Type 1 diabetes is associated with increased cardiovascular disease (CVD)." | ( Ahmed, FW; Glanville, M; Narayanan, K; Razvi, S; Rider, R; Weaver, JU, 2016) |
| "Type 1 diabetes mellitus is a chronic inflammatory disease involving insulin producing β-cells destroyed by the conjoined action of auto reactive T-cells, inflammatory cytokines and monocytic cells." | ( Ajmal, M; Faisal, SM; Fatima, N; Moin, S; Owais, M; Siddiqui, SS; Zubair, S, 2016) |
| "Type 1 diabetes is characterized by the destruction of pancreatic β cells, and generating new insulin-producing cells from other cell types is a major aim of regenerative medicine." | ( Avolio, F; Baburin, I; Barbieux, C; Bennett, KL; Berishvili, E; Bock, C; Briand, F; Casteels, T; Colinge, J; Collombat, P; Courtney, M; Distel, M; Farlik, M; Frogne, T; Gridling, M; Harkany, T; Hecksher-Sørensen, J; Hering, S; Honoré, C; Huber, KVM; Ingvorsen, C; Kimmel, RA; Klughammer, J; Kubicek, S; Lardeau, CH; Li, J; Májek, P; Meyer, D; Parapatics, K; Pauler, FM; Penz, T; Romanov, RA; Schmitner, N; Sdelci, S; Spittler, A; Stukalov, A; Sturtzel, C; Sulpice, T; Superti-Furga, G; Vieira, A, 2017) |
| "Fulminant type 1 diabetes is characterized by remarkably rapid and complete β-cell destruction." | ( Imai, J; Kaneko, K; Katagiri, H; Satake, C; Sawada, S; Takahashi, H; Yamada, T; Yamamoto, J, 2017) |
| "Treatment of type 1 diabetes is based on insulin therapy, which is associated with well-described and unfortunate adverse effects such as hypoglycaemia and increased body weight." | ( Albèr, A; Brønden, A; Knop, FK, 2017) |
| "Type 1 diabetes is a chronic organ-specific autoimmune disease in which selective destruction of insulin-producing β-cells leads to impaired glucose metabolism and its attendant complications." | ( Cheng, P; Fang, J; Jiao, R; Li, T; Li, Z; Liu, X; Ma, Y; Wei, X, 2017) |
| "Type 1 diabetes is associated with such complications as blindness, kidney failure, and nerve damage." | ( Bell, TM; Entwistle, KE; Liu, Y; Pinger, CW; Spence, DM, 2017) |
| "Type 1 diabetes is an autoimmune condition characterised by a pancreatic insulin secretion deficit, resulting in high blood glucose concentrations, which can lead to micro- and macrovascular complications." | ( Bondia, J; Georgiou, P; Herrero, P; Oliver, N, 2017) |
| "Autoimmune diabetes is a disorder of immune homeostasis that leads to targeted insulin-secreting islet β cell destruction characterized by insulitis." | ( Chen, YL; He, L; Li, W; Liao, QY; Qiao, YC; Shen, J; Zhang, QJ; Zhang, XX; Zhao, HL; Zou, X, 2018) |
| "Patients with type 1 diabetes are classified into three subtypes in Japan: acute onset, fulminant and slowly progressive." | ( Fukui, K; Imagawa, A; Iwahashi, H; Kozawa, J; Shimomura, I; Uno, S, 2018) |
| "Type 1 diabetes is a chronic organ-specific autoimmune disease in which selective destruction of insulin-producing β cells leads to impaired glucose metabolism and its attendant complications." | ( Cao, H; Cheng, P; Jiao, R; Li, T; Li, Y; Li, Z; Liu, X; Ma, Y; Tang, J; Wang, M; Wei, X; Xing, Y, 2017) |
| "Type 1 diabetes mellitus is a disease caused by the autoimmune destruction of pancreatic beta-cells." | ( Bossowski, A; Florys, B; Głowińska-Olszewska, B; Jamiołkowska, M; Kalinowska, A; Orlińska, B; Panasiuk, M; Wojtkielewicz, K; Zasim, A; Łuczyński, W, 2017) |
| "Fulminant type 1 diabetes mellitus is characterized by rapid-onset diabetic ketoacidosis, and negative islet-related autoantibodies, and was proposed as a novel subtype of non-autoimmune diabetes." | ( Arihara, Z; Niitsuma, S; Sakurai, K; Sato, R; Takahashi, K, 2018) |
| "Type 1 diabetes is a chronic disease caused by an autoimmune destruction of the insulin-producing cells in the pancreas, leading to a condition with insulin deficiency and elevated blood glucose levels." | ( Ranjan, A, 2018) |
| "Type 1 diabetes is characterized by selective loss of beta cells and insulin secretion, which significantly impact glucose homeostasis." | ( Yosten, GLC, 2018) |
| "Type 1 diabetes is an insulin deficiency-based chronic disease." | ( Antczak, A; Pękala-Wojciechowska, A; Poznański, M; Szyszow, K, 2018) |
| "Type 1 diabetes is by far the most prevalent type of diabetes among Swedish children and adolescents." | ( Marcus, C, 2018) |
| "Type 1 diabetes care requires i) insulin treatment, food intake and life style to be handled in concert, ii) this need cannot be replaced by arbitrary addition of add-on GLDs, and iii) training to this end is 75% cheaper at a DRC than in standard hospitals." | ( Fallmann, H; Hartmann, E; Haslacher, H; Wagner, OF; Waldhäusl, C; Waldhäusl, W, 2018) |
| "Type 1 diabetes is caused by destruction of the pancreatic β‑cells and, to date, no cure has been developed." | ( Huang, C; Li, X; Liu, S; Liu, Y; Mansai, HAA; Wang, T; Wei, W; Yang, S; Zhang, X, 2018) |
| "Type 1 diabetes is characterized by autoimmune destruction of β cells located in pancreatic islets." | ( Jaenisch, R; Ma, H; Melton, DA; Shvartsman, D; Wert, KJ, 2018) |
| "Type 1 diabetes is associated with increased CV risk, especially in persons with cardiovascular autonomic neuropathy (CAN)." | ( Corinth, H; Fuchs, A; Hilsted, J; Hjortkjær, HØ; Jensen, T; Kofoed, KF; Køber, L; Mogensen, UM; Nordestgaard, BG, 2018) |
| "Type 1 diabetes is an autoimmune disease where autoreactive T lymphocytes destroy pancreatic beta cells." | ( Crinò, A; Fierabracci, A; Pellegrino, M; Rosado, MM, 2019) |
| "Type 1 diabetes is a T cell-mediated autoimmune disease." | ( Li, W; Xie, Y; Zhao, Y, 2019) |
| "Though youth with type 1 diabetes are at higher risk for cardiovascular disease, the relationship of inflammation and ambient air pollution exposures in this population has received little attention." | ( Bell, RA; Crume, TL; D'Agostino, RB; Dabelea, D; Dolan, LM; Liese, AD; Marcovina, SM; Mittleman, MA; Montresor-Lopez, J; Pihoker, C; Puett, RC; Reynolds, K; Urbina, E; Yanosky, JD, 2019) |
| "Type 1 diabetes is associated with a higher risk of cardiovascular disease (CVD) in women." | ( Alman, A; Keshawarz, A; Pyle, L; Sassano, C; Sippl, R; Snell-Bergeon, J; Westfeldt, E, 2019) |
| "Although type 1 diabetes mellitus is largely associated with autoimmune thyroid disease and this entity has been recently referred to as autoimmune polyglandular syndrome type 3 variant, the autoimmune polyglandular syndrome type 3 variant in patients with rheumatoid arthritis has not been reported so far." | ( Horino, T; Ichii, O; Ogasawara, M; Terada, Y, 2020) |
| "Type 1 diabetes is associated with atherothrombosis, but limited data exist on procoagulant activity in the young." | ( Arnesen, H; Bratseth, V; Dahl-Jørgensen, K; Heier, M; Margeirsdottir, HD; Seljeflot, I; Solheim, S, 2020) |
| "Type 1 diabetes is a risk factor for coronary heart disease." | ( Berg, TJ; Hanssen, KF; Holte, KB; Monnier, VM; Seljeflot, I; Sell, DR; Solheim, S; Svanteson, M; Sveen, KA, 2020) |
| "Type 1 diabetes is an autoimmune disease caused by the destruction of the insulin-producing β-cells." | ( Aguilera, E; Ampudia, RM; Cano-Sarabia, M; Coma, M; Gomez-Muñoz, L; Perna-Barrull, D; Pujol-Autonell, I; Rodriguez-Fernandez, S; Vázquez, F; Verdaguer, J; Villalba, A; Vives-Pi, M, 2020) |
| "Type 1 diabetes is a chronic autoimmune disease of beta cells in the islets of Langerhans, which are responsible for making insulin." | ( Ahmadiafshar, S; Hosseini, G; Jafari Khataylou, Y; Parsamanesh, S; Rezaei, R, 2020) |
| "Type 1 diabetes is a metabolic disorder caused by the loss or dysfunction of β-cells in the pancreas." | ( Absalan, M; Ai, J; Barabadi, Z; Jabbarpour, Z; Karimi, R; Larijani, B; Lotfibakhshaiesh, N; Ostad, SN; Tavoosidana, G, 2021) |
| "Type 1 diabetes is an autoimmune disease caused by the destruction of the insulin-producing β-cells." | ( Aguilera, E; Ampudia, RM; Cano-Sarabia, M; Gomez-Muñoz, L; Maspoch, D; Perna-Barrull, D; Pujol-Autonell, I; Risueño, RM; Rodriguez-Fernandez, S; Vázquez, F; Villalba, A; Vives-Pi, M, 2020) |
| "Type 1 diabetes is an autoimmune disease characterized by progressive loss of pancreatic beta cells." | ( Felner, EI; Haller, MJ; Hedrick, JA; Leu, JH; Li, Y; Quattrin, T; Rigby, MR; Steck, AK; Vercruysse, F; Xia, Y; Zoka, R, 2020) |
| "Type 1 diabetes is an autoimmune disease resulting in severely impaired insulin secretion." | ( Messinger Cayetano, S; Pastori, R; Pugliese, A; Snowhite, I; Sosenko, J, 2021) |
| "Type 1 diabetes is characterised by progressive loss of functional β-cell mass, necessitating insulin treatment." | ( Bain, SC; Bode, B; Clausen, JO; Coppieters, K; Gaysina, L; Gumprecht, J; Hansen, TK; Mathieu, C; Morales, C; Mosenzon, O; Pieber, TR; Segel, S; Tsoukas, G; von Herrath, M, 2021) |
| "The incidence of type 1 diabetes is increasing more rapidly than can be explained by genetic drift." | ( Buschard, K; Dahl-Jørgensen, K; Gerling, IC; Haupt-Jorgensen, M; Kaur, S; Krogvold, L; Pedersen, K; Pociot, F, 2021) |
| "Type 1 diabetes is characterized by insulin deficiency and requires near-physiological insulin replacement." | ( Fabricius, TW; Pedersen-Bjergaard, U; Thorsteinsson, B, 2021) |
| "Type 1 diabetes is an autoimmune disease that results in the specific destruction of insulin-producing beta cells in the pancreas." | ( Han, Y; Pan, L; Wang, Q; Xu, M; Zhou, Z; Zou, X, 2022) |
| "Type 1 diabetes is a chronic immune-mediated disease caused by pancreatic β-cell dysfunction with consequent severe insulin deficiency." | ( Chakrapani, LN; Gopinath, B; Kannan, P; Karthikeyan, P; Mohan, T; Palanivelu, S; Periandavan, K; Raghunathan, M; Subramaniam, N, 2022) |
| "Type 1 diabetes mellitus is an autoimmune disorder leading to loss of beta cells." | ( Arvindekar, A; Damame, H; Garad, C; Patil, R; Rooge, S, 2022) |
| "Fulminant type 1 diabetes mellitus is known to be associated with pregnancy and had been associated with high fetal mortality." | ( Mohd Noor, N; Ting Tai, Y, 2022) |
| "Older adults with type 1 diabetes are recommended modified glucose targets." | ( Alipoor, AM; Colman, PG; Fourlanos, S; Grills, CA; Lee, MH; MacIsaac, RJ; McAuley, SA; O'Neal, DN; O'Regan, NA; Sundararajan, V; Trawley, S; Vogrin, S; Ward, GM, 2022) |
| "Older adults with type 1 diabetes are recommended modified glucose targets." | ( Alipoor, AM; Colman, PG; Fourlanos, S; Grills, CA; Lee, MH; MacIsaac, RJ; McAuley, SA; O'Neal, DN; O'Regan, NA; Sundararajan, V; Trawley, S; Vogrin, S; Ward, GM, 2022) |
| "Older adults with type 1 diabetes are recommended modified glucose targets." | ( Alipoor, AM; Colman, PG; Fourlanos, S; Grills, CA; Lee, MH; MacIsaac, RJ; McAuley, SA; O'Neal, DN; O'Regan, NA; Sundararajan, V; Trawley, S; Vogrin, S; Ward, GM, 2022) |
| "Type 1 diabetes is associated with altered exocrine function, even before onset." | ( Bakinowska, L; Chandler, K; Feldmann, M; Gillespie, KM; Jerram, ST; Johnson, DG; Leslie, RD; Long, AE; Patel, KA; Phuthego, T; Taylor, M; Vartak, T; Williams, AJK; Williams, S, 2023) |
| "Type 1 diabetes mellitus is the most common type of diabetes mellitus in children and adolescents, accounting for about 90% of diabetes in the population under the age of 18." | ( Grywalska, E; Hymos, A; Klatka, M; Mertowska, P; Mertowski, S; Polak, A; Rysz, I; Smolak, K, 2023) |
| "Fulminant type 1 diabetes is a recently recognized diabetes subtype characterized by extremely rapid destruction of the pancreatic beta cells, leading to an absolute deficiency in insulin secretion." | ( Chung, DJ; Chung, JO; Kim, J; Kim, K; Park, SY, 2023) |
| "Type 1 diabetes mellitus is widely recognized as a chronic autoimmune disease characterized by the pathogenic destruction of beta cells, resulting in the loss of endogenous insulin production." | ( Ahmed Rizvi, SH; Ahmed, SH; Asghar, MS; Ashraf, MT; Kashif, MAB; Shakeel Khan, MK, 2023) |
| "Type 1 diabetes is an autoimmune disease associated with the destruction of insulin-producing β cells." | ( Kinney, SM; Licht, BJM; Ortaleza, K; Sefton, MV; Won, SY, 2023) |
| "Type 1 diabetes is a growing metabolic disorder, its ultimate therapy is the use of taking insulin regularly but, despite of that these patients cannot survive for longer durations due to poor glycaemic control, insulin resistance and development of complications." | ( Amina Raza, -; Asher Fawwad, -; Fasiha Fatima, -; Iftikhar Ahmed, -; Madiha Soban, -; Ruqaya Nangrejo, -, 2023) |
| Excerpt | Reference |
|---|
| "Twenty-nine IDDM patients with borderline hypertension were randomly allocated to placebo or nitrendipine treatment." | ( Gries, FA; Homberg, M; Roesen, P; Tschoepe, D, 1992) |
| "A 71-year-old man with type I diabetes mellitus was admitted to the hospital for the treatment of osteomyelitis of the left great toe secondary to methicillin-resistant Staphylococcus aureus." | ( Dretler, RH; Frye, RF; Job, ML; Rosenbaum, BJ, 1992) |
| "Nine patients with Type I diabetes mellitus, diastolic blood pressure of 90 to 100 mmHg and persistent microalbuminuria of greater than or equal to 30 micrograms/min were treated with 50 to 100 mg atenolol daily for 3 years in an uncontrolled pilot study to assess the effect of long-term reduction of blood pressure on microalbuminuria." | ( Davies, JA; Stickland, M; Tindall, H; Urquhart, S, 1991) |
| "The overall incidence of IDDM was unaffected by treatment." | ( Baskin, DG; Beck, JC; Braquet, P; Glidden, D; Goodner, CJ; Lernmark, A; Wilson, C; Wilson, D, 1991) |
| "Among NIDDM patients, abnormal IgA concentrations were especially prevalent among those being treated with oral hypoglycemics." | ( Camiña, MF; Del Río, R; Paz, JM; Rodríguez-Segade, S, 1991) |
| "In this study, six IDDM patients receiving ultralente-based intensive insulin therapy were studied during 30 min of exercise (approximately 60% VO2max), before breakfast, and at 1600." | ( Cryer, PE; Haymond, MW; Marsh, HM; Miles, JM; Rizza, RA; Ruegemer, JJ; Squires, RW, 1990) |
| "Sixteen IDDM patients aged 12-31 years, recruited within 2 weeks of initiation of insulin therapy and within 5 weeks of onset of symptoms, were treated with intravenous (i." | ( Amato, MP; Galluzzo, A; Giordano, C; Pantŏ, F; Pugliese, A; Sapienza, N, 1990) |
| "These data suggest that treatment of Type 1 diabetes with nicotinamide at diagnosis is associated with a moderate increase of C-peptide secretion recovery." | ( Casamitjana, R; Gomis, R; Mendola, G, 1989) |
| "We describe a patient with type I diabetes mellitus and hypothyroidism who developed frank adrenocortical insufficiency while receiving a high-dose ketoconazole therapy for keratitis caused by Acanthamoeba species." | ( Demerjian, Z; Godine, JE; Khosla, S; Wolfson, JS, 1989) |
| "Recognizing the similarity of type I diabetes mellitus to inborn errors of metabolism that have responded to carnitine therapy, we initiated a study of 54 children with type I diabetes mellitus." | ( Higashi, L; O'Hara, T; Simon, M; Szabo-Aczel, S; Vance, WH; Winter, SC; Zorn, EM, 1989) |
| "We conclude that in IDDM and in totally pancreatectomized patients, administration of insulin with subsequent normalization of blood glucose is accompanied by a decline in plasma levels of SLI in the fasted state, whereas the apparent response to a meal is enhanced." | ( Efendić, S; Grill, V; Gutniak, M; Wiechel, KL, 1987) |
| "The cumulative incidence of IDDM over 20 wk in the OK-432-treated BB rats (4 of 54, 7." | ( Goto, Y; Nobunaga, T; Oya, K; Satoh, J; Shintani, S; Tanaka, S; Toyota, T, 1988) |
| "bolus form into 21 insulin-dependent (IDDM) and 22 noninsulin-dependent (NIDDM) diabetics before and one to three months after strict glycemic control with multiple insulin injection therapy or continuous subcutaneous insulin infusion therapy." | ( Katsura, M, 1986) |
| "In 6 IDDM women, the influence of the hormonal treatment on diabetes control and on ovarian function was investigated by measuring the concentration of glycosylated hemoglobin (Hb-Alc), fasting plasma glucose, serum estradiol, serum estrone, serum progesterone and sex hormone binding globulin (SHBG) capacity." | ( Jensen, BM; Kühl, C; Mølsted-Pedersen, L; Nielsen, J; Skouby, SO; Svenstrup, B, 1985) |
| "At onset of IDDM, serum and blood clot zinc concentrations were reduced with a gradual increase towards normal within 1 month of insulin therapy." | ( Falkmer, S; Hägglöf, B; Hallmans, G; Holmgren, G; Ludvigsson, J, 1983) |
| "Cytotoxic antibodies decreased in most IDDM subjects treated by plasmapheresis four times within 2 wk of diagnosis; however, the decreases were small and lasted less than 2-3 days." | ( Lernmark, A; Ludvigsson, J; MacKay, P; Rabinovitch, A, 1984) |
| "(2) In 27 newly diagnosed cases of IDDM, the group receiving CSII (n = 18) showed more satisfactory results, including greater stability of blood glucose, a more rapid decrease in insulin requirements and an earlier improvement in u-CPR compared to the control group who were receiving conventional subcutaneous insulin therapy (n = 9)." | ( Amemiya, S; Asayama, K; Kato, K, 1983) |
| "In 105 children and adolescents with IDDM, insulin antibodies were detected as a percentage of radiolabelled insulin both at onset of disease and during the first 8 years of treatment." | ( Cacciari, E; Donati, S; Gualandi, S; Mandini, M; Mantovani, W; Salardi, S; Steri, L; Zucchini, S, 1995) |
| "For the first time, we studied 27 type 1 diabetes patients treated with NA for 12 months and then followed up for 1 year after discontinuance of NA." | ( Baroni, MG; Boccuni, ML; Buzzetti, R; Cavallo, MG; Fioriti, E; Mesturino, C; Pozzilli, P; Signore, A; Valente, L; Visalli, N, 1995) |
| "We studied 21 IDDM patients with hypoglycaemia unawareness and frequent mild/severe hypoglycaemia episodes while on "conventional" insulin therapy, and 20 nondiabetic control subjects." | ( Annibale, B; Ciofetta, M; Di Vincenzo, A; Epifano, L; Fanelli, C; Lepore, M; Modarelli, F; Pampanelli, S; Rambotti, AM; Torlone, E, 1994) |
| "Eighteen hypertensive IDDM patients with diabetic nephropathy, who had not been treated previously, were followed during 3 years of treatment with captopril and frusemide or bendrofluazide." | ( Hommel, E; Parving, HH; Rossing, P; Smidt, UM, 1994) |
| "Twelve of the subjects with IDDM and six normal subjects received pirenzepine 200 mg and pyridostigmine 120 mg pretreatment 60 minutes and GH pretreatment 3 hours before an i." | ( Ismail, IS; Peters, JR; Scanlon, MF, 1993) |
| "Eight of the IDDM subjects were on continuous subcutaneous insulin infusion (insulin pump), and four were on conventional twice-daily insulin treatment." | ( Denne, SC; Kalhan, SC; Nuamah, IF; Patel, DM; Savin, SM, 1994) |
| "The incidence of IDDM was significantly reduced when these animals were treated with 2 or 4 mg fusidic acid (FA)/day i." | ( Bendtzen, K; Di Marco, R; Grasso, S; Lembo, D; Meroni, PL; Morrone, S; Nicoletti, F; Santoni, A; Zaccone, P, 1994) |
| "Six adult patients with IDDM were studied on conventional insulin therapy and after 2 mo of intensive insulin therapy while maintaining constant caloric intake and were compared with a group of 6 matched nondiabetic volunteers." | ( Campbell, PJ; Carlson, MG, 1993) |
| "In another model of IDDM, the multiple-low-dose streptozocin-injected mouse, MDL (1%) also reduced the prevalence of diabetes when administered beginning 8 wk before streptozocin (55% diabetic vs." | ( Dillberger, JE; Heineke, EW; Johnson, MB; Robinson, KM, 1993) |
| "Seven nondiabetic and seven IDDM pregnant patients on insulin pump therapy were studied at the first trimester." | ( Aoki, TT; Foss, MC, 1993) |
| "Some 205 patients aged 10-18 yr with IDDM, who were previously treated with two daily insulin injections, were included without any selection into a randomized trial." | ( Asensi, D; Bougnères, PF; Chavoix, P; Garandeau, P; Jais, JP; Jos, J; Landais, P; Mairesse, AM; Peyraud, J; Wieliczko, MC, 1993) |
| "Prophylactic insulin therapy prevents IDDM in spontaneous animal models of the disease and has shown promise in preventing the disease in humans." | ( Atkinson, MA; Bowman, MA; Campbell, L; Darrow, BL; Ellis, TM; Suresh, A, 1996) |
| "It is concluded that in IDDM, even if normoglycemia is managed, there is significantly increased amino acid catabolism with posthepatic systemic insulin treatment." | ( Fischer, U; Freyse, EJ; Petrzika, M; Rebrin, K; Schneider, T, 1996) |
| "As our model we selected type 1 diabetes with peripheral circulatory hyperinsulinemia induced by sc insulin treatment." | ( Gromeier, S; Kerner, W; Kohlmann, T; Look, D; Peters, A, 1996) |
| "In seven patients with IDDM with strict glycemic control and hypoglycemia unawareness, responses were studied with the use of a hyperinsulinemic hypoglycemic clamp test before and after 3 months of test treatment, which aimed at increasing daily mean blood glucose levels to 8 to 10 mmol/L, based on self-monitoring four times per day." | ( Liu, D; McManus, RM; Ryan, EA, 1996) |
| "Patients with moderately controlled type I diabetes mellitus have normal baseline and stimulated GH concentrations after the administration of GHRH or clonidine compared with healthy controls, when corrected for age, body mass index and sex." | ( Blankestijn, PJ; Jacobs, ML; Nathoe, HM; Stijnen, T; Weber, RF, 1996) |
| "Eight IDDM nephrotic patients planning pregnancy were treated with captopril for a minimum of 6 months prior to conception together with intensive insulin management." | ( Bar, J; Boner, G; Erman, A; Hod, M; Karp, M; Ovadia, J; Peled, Y; Rabinerson, D; van Dijk, DJ; Weintraub, N, 1995) |
| "Within the group of IDDM patients, hemoglobin A1c was inversely correlated with forearm blood flow during administration of acetylcholine (r = -." | ( Cockcroft, J; Fagerudd, J; Groop, PH; Mäkimattila, S; Utriainen, T; Virkamäki, A; Yki-Järvinen, H, 1996) |
| "Sera from 9 IDDM patients with the same clinical characteristics and followed up for 12 months represented the control group (insulin therapy only)." | ( d'Ambrosio, C; De Ciocchis, A; Letizia, C; Pozzilli, P; Scavo, D, 1995) |
| "Ten men with Type 1 diabetes mellitus participated in a randomized, double-blind, crossover, clinical trial with three treatment regimens, namely (1) insulin alone, (2) insulin and placebo, (3) insulin and glibenclamide, each lasting 3 months." | ( Birkenholz, M; Kabadi, M; Kabadi, UM; McCoy, S, 1995) |
| "We have shown that in IDDM this disturbance is closely linked to iatrogenic hyperinsulinemia (HI), because it was reversed when insulin was administered by the intraportal (i." | ( Bagdade, JD; Gabfr, O; Huss, E; Kitabchi, AE; Lambeth, H; Ritter, MC; Thistlethwaite, R, 1996) |
| "The results suggest that in NIDDM hypertriglyceridemia should be treated to reduce the high risk for atherosclerosis." | ( Hoogerbrugge, N; Jacobs, ML; Jongkind, JF; Postema, PT; Verkerk, A, 1996) |
| "Thirty-six normotensive IDDM patients with diabetic nephropathy were included; 18 were treated with fish oil." | ( Hansen, BV; Hølmer, G; Myrup, B; Nielsen, FS; Parving, HH; Rossing, P, 1996) |
| "Patients with NIDDM were divided in the groups according to: sex, duration of disease, a kind of complications and a way of treatment." | ( Knapik-Kordecka, M; Piwowar, A; Warwas, M, 1996) |
| "Bone formation at onset of IDDM is not impaired; the introduction of insulin therapy, together with the achievement of a good metabolic control, determines an increase of bone matrix formation coupled with a decrease of bone resorption, that determines a positive balance of bone modeling." | ( Bognetti, E; Bonfanti, R; Chiumello, G; Meschi, F; Mora, S; Prinster, C; Proverbio, MC; Puzzovio, M, 1997) |
| "2) The basic prolactin secretion in IDDM patients with diabetic nephropathy in the end stage renal failure treated with haemodialysis was significantly lower than in haemodialyzed patients with chronic renal failure of non-diabetic etiology." | ( Gawron, J; Grzeszczak, W; Gumprecht, J; Liszka, M; Moczulski, D; Snit, M; Zukowska-Szczechowska, E, 1996) |
| "We conclude that intensively treated IDDM patients are resistant to changes in cortical evoked potentials induced by mild hypoglycemia." | ( Borg, MA; Borg, WP; Boulware, SD; Jones, TW; McCarthy, G; Sherwin, RS; Silver, D; Tamborlane, WV, 1997) |
| "Protection against IDDM by dCF was time dependent and only occurred if treatments were initiated by day 30 of age." | ( Begleiter, A; Johnston, JB; Manchur, D; Thliveris, JA, 1997) |
| "Thus, intensive insulin therapy in IDDM subjects brought quantitative lipoprotein alterations to normal even subnormal range, while most of the composition abnormalities improved without reaching complete normalization." | ( Caixàs, A; Carreras, G; de Leiva, A; Gómez-Gerique, J; Mauricio, D; Pérez, A; Pou, JM; Serrat, J, 1997) |
| "In patients with IDDM given an evening dose of NPH insulin, a conventional bedtime snack exerts an inconsistent glycemic effect only during the first half of the night, and bedtime administration of the glucagon-releasing amino acid alanine or the epinephrine-simulating beta2-adrenergic agonist terbutaline more effectively prevents nocturnal hypoglycemia than a conventional bedtime snack." | ( Cryer, PE; Saleh, TY, 1997) |
| "Thirty-five IDDM patients with incipient nephropathy were randomized to treatment with placebo, unfractioned heparin, or low molecular weight heparin in a double-blind trial." | ( Deckert, T; Gram, J; Jensen, T; Jespersen, J; Kluft, C; Myrup, B, 1997) |
| "Intensive therapy for type 1 diabetes helps sustain endogenous insulin secretion, which, in turn, is associated with better metabolic control and lower risk for hypoglycemia and chronic complications." | ( , 1998) |
| "GLP-1 lowers blood glucose in both NIDDM and IDDM patients and may be therapeutically useful for treatment of patients with diabetes." | ( Drucker, DJ, 1998) |
| "Ninety-two normotensive IDDM patients underwent double-blind, double-dummy treatment with either lisinopril or slow-release nifedipine in comparison with placebo." | ( Carta, Q; Crepaldi, G; Deferrari, G; Mangili, R; Navalesi, R; Nosadini, R; Santeusanio, F; Spalluto, A; Vanasia, A; Villa, GM, 1998) |
| "In seven microalbuminuric IDDM patients, systemic and renal responsiveness to NE, infused at individually determined threshold [deltamean arterial pressure (MAP)=0 mmHg], 20% pressor (deltaMAP=4 mmHg) and pressor (deltaMAP=20 mmHg) doses, were compared before and after 8 weeks treatment with enalapril, 10 mg daily." | ( Dullaart, RP; Hoogenberg, K; Navis, G, 1998) |
| "In the NIDDM group, the ratio of insulin treatment tended to be higher in subjects homozygous for the G3 allele, although the genotype was not significantly associated with basal C-peptide levels." | ( Hayashi, H; Ichikawa, F; Ishiyama, S; Kohno, S; Nonaka, K; Shoji, S; Yamada, K; Yuan, X, 1998) |
| "As IDDM and non-obese NIDDM presented great similarities before treatment, even for C-peptide levels, a point score system is proposed to classify these two groups at baseline." | ( Cuisinier-Raynal, JC; Darrack, R; Delcourt, C; Lokrou, A; Papoz, L; Ponton-Sanchez, A; Touré, IA, 1998) |
| "Subjects included 30 young IDDM patients with microalbuminuria who were randomized to receive either continuous subcutaneous insulin infusion (CSII) by a portable insulin pump (n = 15) or conventional insulin treatment (CIT) (n = 15) for 24 months." | ( Bangstad, HJ; Berg, TJ; Hanssen, KF; Nourooz-Zadeh, J; Tritschler, HJ; Wolff, SP, 1998) |
| "Risk factors associated with IDDM and IGT were lack of compliance with chelation therapy, iron overload and the presence of cirrhosis and severe fibrosis." | ( De Sanctis, V; Fortini, M; Gamberini, MR; Gilli, G; Testa, MR, 1998) |
| "In recent-onset type 1 diabetes, nicotinamide administration improves beta-cell function, without significantly decreased insulin requirements." | ( Burkart, V; Kolb, H, 1999) |
| "Although IDDM causes immense morbidity and expense, uniformly effective preventive or beta-cell protective therapy is not currently available." | ( Sjöholm, A, 1998) |
| "The mechanism behind bone fragility in IDDM is multifactorial and despite a restored renal function bone disease may progress, and is probably enhanced by the immunosuppressive treatment." | ( Backman, U; Fellström, B; Lindh, E; Ljunghall, S; Nisbeth, U, 1999) |
| "A total of 34 patients with type 1 diabetes were studied under euglycemic conditions on two occasions (11 without microangiopathy, 10 with proliferative and preproliferative retinopathy previously treated by laser coagulation, 13 with microalbuminuria, and 12 healthy volunteers also were studied)." | ( De Haan, CH; De Leeuw, PW; Hamulyak, K; Houben, AJ; Huvers, FC; Schaper, NC; Schouten, H; Wolffenbuttel, BH, 1999) |
| "Treatment of type 1 diabetes mellitus has made tremendous advances within the last decades." | ( Haak, T, 1999) |
| "In contrast, rhIL-11 failed to prevent type 1 diabetes when administered for the first time to euglycemic 18-week-old NOD mice." | ( Bendtzen, K; Conget, I; Gomis, R; Meroni, PL; Möller, C; Nicoletti, F; Sandler, S; Trepicchio, W; Zaccone, P, 1999) |
| "A 17-year-old boy with type 1 diabetes mellitus developed new loss of hypoglycemia awareness while being treated with fluoxetine hydrochloride for depression." | ( Burgart, V; Sawka, AM; Zimmerman, D, 2000) |
| "Registry data on patients with type 1 diabetes mellitus who undergo pancreatic islet transplantation indicate that only 8 percent are free of the need for insulin therapy at one year." | ( Kneteman, NM; Korbutt, GS; Lakey, JR; Rajotte, RV; Ryan, EA; Shapiro, AM; Toth, E; Warnock, GL, 2000) |
| "Patients with type 1 diabetes receiving basal-bolus insulin treatment with NPH human insulin and insulin lispro were randomized to receive insulin glargine (HOE 901), a long-acting basal insulin analog, once a day (n = 310) or NPH human insulin (n = 309) as basal treatment with continued bolus insulin lispro for 16 weeks in an open-label study NPH insulin patients maintained their prior schedule of administration once or twice a day, whereas insulin glargine patients received basal insulin once a day at bedtime." | ( Bergenstal, R; Donley, D; Hallé, JP; Klaff, L; Mecca, T; Raskin, P, 2000) |
| "Forty-nine patients (34 with Type 1 diabetes, 15 with Type 2 diabetes) had no antioxidant treatment and served as a control group." | ( Amiral, J; Borcea, V; Ehret, T; Gehrke, S; Henkels, M; Hofmann, M; Isermann, B; Morcos, M; Nawroth, PP; Schiekofer, S; Tritschler, H; Wahl, P; Ziegler, R, 2001) |
| "Drivers with Type 1 Diabetes Mellitus (T1DM) who did and did not engage in self-treatment during experimental hypoglycemia driving are compared physiologically and psychologically." | ( Clarke, WL; Cox, DJ; Gonder-Frederick, LA; Kovatchev, BP, 2001) |
| "Insulin-dependent diabetes mellitus (IDDM) is difficult to live with as well as difficult to treat among adolescents." | ( Tubiana-Rufi, N, 2001) |
| "We treated 10 newly diagnosed type 1 diabetes patients with 30,000 IU ingested interferon-alpha (IFN-alpha) within 1 month of diagnosis and examined the difference between baseline and Sustacal-induced (Mead Johnson Nutritionals, Evansville, IN) C-peptide responses, respectively, at 0, 3, 6, 9, and 12 months." | ( Atkinson, M; Brod, SA; Brosnan, PG; Hardin, DS; Lavis, VR; Nguyen, M; Orlander, PR; Riley, WJ, 2001) |
| "One possible treatment for type 1 diabetes is the development of beta-cell substitutes by introducing an insulin-producing gene into non-beta cells, which would evade the beta-cell-specific autoimmune attack." | ( Jun, HS; Yoon, JW, 2002) |
| "A total of 47 randomised IDDM children were recruited from those treated at the Endocrinology Unit of the University Hospital of Granada (Spain)." | ( Baena, RM; Bayés, R; Blanca, E; Campoy, C; Fernández, JM; Molina-Font, JA, 2002) |
| "Insulin replacement therapy in type 1 diabetes is imperfect because proper glycemic control is not always achieved." | ( Bosch, F; Ferre, T; Gros, L; Mas, A; Montoliu, L; Otaegui, P; Pujol, A; Riu, E, 2002) |
| "Intensive insulin treatment of type 1 diabetes mellitus increases the risk for nocturnal hypoglycemia." | ( Bolli, GB; Brunetti, P; Fanelli, CG; Pampanelli, S; Porcellati, F; Rossetti, P, 2002) |
| "When the goal of insulin therapy in type 1 diabetes mellitus is near-normoglycemia, splitting the evening insulin treatment regimen into short-acting insulin at dinner and NPH insulin at bedtime reduces the risks for nocturnal hypoglycemia and hypoglycemia unawareness and decreases the hemoglobin A1c value compared with mixing short-acting insulin and NPH insulin at dinner." | ( Bolli, GB; Brunetti, P; Fanelli, CG; Pampanelli, S; Porcellati, F; Rossetti, P, 2002) |
| "Ten patients with type 1 diabetes (four female, mean age 33 +/- 3 years, diabetes duration 12 +/- 2 years) participated in an open, randomized cross-over study, with 2 months run-in and 4-month treatment periods using either lispro or human-soluble insulin before meals and human NPH insulin (NPH) at night." | ( Amiel, SA; Evans, ML; Heller, SR; Kong, MF; Macdonald, IA; Peacey, SR, 2002) |
| "The use of cyclosporin in recent-onset type 1 diabetes has demonstrated the potential for immune intervention in the treatment and prevention of the disease." | ( Carstensen, B; Christie, MR; Hawkes, CJ; Mandrup-Poulsen, T; Mølvig, J, 2002) |
| "However, in type 1 diabetes the benefits of mealtime treatment with rapid-acting insulin analogues become apparent only to the extent that replacement of basal insulin is optimised." | ( Bolli, GB, 2002) |
| "Insulin treatment is essential in Type 1 diabetes mellitus (DM)." | ( Ekberg, K; Hjemdahl, P; Hu, H; Johansson, BL; Li, N, 2002) |
| "Eight normal subjects and six IDDM subjects treated with twice-daily intermediate- and short-acting insulin consumed a mixed test meal containing 0." | ( Hamadeh, MJ; Hoffer, LJ, 2003) |
| "Insulin-dependent diabetes mellitus (IDDM) model BB/Wor//Tky (BB) rats exhibit both hyperglycemia and hyperlipidemia and die within 3 weeks after the onset of diabetes unless insulin therapy is given." | ( Kawazu, S; Komeda, K; Lu, D; Takeuchi, T; Zhang, W, 2002) |
| "Eleven adolescent girls with type 1 diabetes and poor metabolic control were investigated before and after treatment with PZP, 100 mg orally, twice a day for 3 weeks." | ( Brismar, K; Gustafsson, J; Halldin, MU; Tuvemo, T, 2002) |
| "Patients with type 1 diabetes continue to experience increased risk of hypoglycemic episodes and progressive weight gain resulting from intensive insulin treatment, despite the recent availability of a variety of insulin analog." | ( Baron, AD; Kim, D; Weyer, C, 2002) |
| "A gene-therapy-based treatment of type 1 diabetes mellitus requires the development of a surrogate beta cell that can synthesize and secrete functionally active insulin in response to physiologically relevant changes in ambient glucose levels." | ( Alam, T; Sollinger, HW, 2002) |
| "Patients with type 1 diabetes under intensive insulin therapy tend to normalize the clinical parameters of glycemic control, although this improvement does not significantly affect biochemical markers of vitamin A and E status." | ( Blanco, I; Botella, F; Granado, F; Olmedilla, B; Simal, A, 2003) |
| "A total of 18 patients with type 1 diabetes treated by external pump were studied during pump stop for 5 h." | ( Benichou, M; Bohme, P; Drouin, P; Floriot, M; Fougnot, S; Franck, P; Guerci, B, 2003) |
| "A total of 51 patients with type 1 diabetes on intensive therapy (NPH four times/day and lispro insulin at each meal) were randomized to three different regimens of basal insulin substitution while continuing lispro insulin at meals: continuation of NPH four times/day (n = 17), once daily glargine at dinnertime (n = 17), and once daily glargine at bedtime (n = 17) for 3 months." | ( Bolli, GB; Costa, E; Fanelli, C; Pampanelli, S; Porcellati, F; Rossetti, P; Scionti, L; Torlone, E, 2003) |
| "Patients with type 1 diabetes on basal-bolus therapy (n = 378, 18-68 years, HbA(1c) 5." | ( Hamann, A; Matthaei, S; Rosak, C; Silvestre, L, 2003) |
| "Adult men with fairly controlled type 1 diabetes without complications who are treated with subcutaneous insulin have a tendency to hypogonadism, as reflected by lower free testosterone levels in the presence of similar total testosterone levels and higher SHBG levels." | ( Dekker, JM; Krans, HM; Lentjes, EG; Post, WJ; Romijn, FP; Romijn, JA; Smulders, YM; van Dam, EW, 2003) |
| "In newly detected type 1 diabetes patients, before insulin therapy, urine PC-1 excretion was significantly increased (P<0." | ( Antić, S; Ivić, MA; Mitić-Zlatković, M; Rajić, M; Stefanović, V; Stojiljković, S; Vlahović, P, 2003) |
| "Treatment with CSII in patients with Type 1 diabetes is associated with increased plasma fibrin gel porosity." | ( Blombäck, M; Hansson, LO; Jörneskog, G; Wallen, NH; Yngen, M, 2003) |
| "In patients with type 1 diabetes, especially in combination with associated organ-specific autoimmune diseases, autoimmune polyglandular syndrome should be considered and adequately treated with those hormones that are reduced." | ( Hübinger, A; Scherbaum, WA; Schloot, NC, 2003) |
| "This study demonstrates that autoimmune diabetes recurrence after islet transplantation could be prevented by treatment with LSF." | ( Carter, JD; Chen, M; Ellett, JD; Fialkow, LB; Nadler, JL; Yang, Z, 2004) |
| "The incidence of IDDM was significantly higher among tacrolimus-treated patients (10." | ( Balshaw, R; Heisel, O; Heisel, R; Keown, P, 2004) |
| "FTY720 can prevent autoimmune diabetes, if administered before and/or during stimulation and expansion of the autoreactive T cells or in the early stages of insulitis." | ( Kover, KL; Moore, WV; Popovic, J, 2004) |
| "People with type 1 diabetes (n = 408) were randomized in an open-label, parallel-group trial of 16-week treatment duration using either insulin detemir or NPH insulin." | ( Abrams, P; Bartley, P; Draeger, E; Hanaire-Broutin, H; Heeg, JE; Home, P; Hylleberg, B; Landin-Olsson, M; Lang, H; Russell-Jones, D, 2004) |
| "One of the patients developed type 1 diabetes five months after start of treatment." | ( Peters, T; Rasenack, J; Reincke, M; Schories, M, 2004) |
| "However, it has been reported that autoimmune diabetes can be induced by oral administration of an auto-antigen (insulin), and great caution is therefore warranted when applying the oral tolerance approach to prevent Type 1 diabetes." | ( Benderly, A; Etzioni, A; Shamir, R; Shehadeh, N; Teninboum, G; Weis, R, 2004) |
| "Thirty-two youth with type 1 diabetes (age 8-21 years) were randomly assigned to receive either MDI treatment with once-daily glargine and premeal/snack insulin aspart or CSII with insulin aspart." | ( Ahern, JA; Doyle, EA; Steffen, AT; Tamborlane, WV; Vincent, M; Weinzimer, SA, 2004) |
| "In summary, in type 1 diabetes, glucagon modulation with pramlintide as an adjunct to insulin therapy may prove beneficial in controlling postmeal glycemic swings." | ( Bomgaars, L; Haymond, MW; Heptulla, RA; Rodriguez, LM, 2005) |
| "For selected patients with type 1 diabetes mellitus and end-stage renal failure, simultaneous kidney-pancreas (SKP) or pancreas after kidney (PAK) transplantation is the treatment of choice." | ( Aguirrezabalaga, J; Alonso, A; Fernández, C; García, R; Gómez, M; Oliver, J; Valdés, F; Villaverde, P, 2005) |
| "A 2-year-old boy with type I diabetes mellitus was admitted due to a coma caused by cerebral oedema and was successfully treated for his neurological condition but presented on the tenth day after admission with fever of 40 degrees C, agitation, restlessness, lack of appetite, somnolence and fatigue." | ( Cascio, A; Costa, GB; Crisafulli, G; Iaria, C; Ruggeri, C; Rulli, I; Stassi, G, 2005) |
| "Orally administered VSL#3 prevents autoimmune diabetes and induces immunomodulation by a reduction in insulitis severity." | ( Boirivant, M; Bonato, V; Calcinaro, F; Candeloro, P; Corneli, RB; De Simone, C; Di Mario, U; Dionisi, S; Dotta, F; Falorni, A; Ferretti, E; Grasso, F; Gulino, A; Marinaro, M; Marzotti, S, 2005) |
| "Early treatment of newly diagnosed type 1 diabetes patients with intermittently administered fusidin failed to influence the natural course of the disease." | ( Aguilera, E; Bendtzen, K; Casamitjana, R; Conget, I; Gomis, R; Näf, S; Nicoletti, F; Pellitero, S, 2005) |
| "Ten children with newly diagnosed type 1 diabetes (10-17 y) were treated with five double treatments of photopheresis and 10 children matched for disease, age, and gender were given placebo tablets and sham pheresis." | ( Berlin, G; Ernerudh, J; Faresjö, MK; Garcia, J; Ludvigsson, J, 2005) |
| "Diagnosis of type 1 diabetes was based on permanent insulin treatment or a fasting C-peptide level < or =0." | ( Bruno, G; Cavallo-Perin, P; Cerutti, F; Merletti, F; Novelli, G; Pagano, G; Pinach, S; Rivetti, M; Runzo, C; Trovati, M, 2005) |
| "The onset of type 1 diabetes in NOD mice is delayed by oral administration of a bacterial extract (OM-85) and can be completely prevented by its intraperitoneal administration." | ( Alyanakian, MA; Aumeunier, A; Bach, JF; Bardel, E; Chatenoud, L; Chiavaroli, C; Gouarin, C; Grela, F; Normier, G; Thieblemont, N, 2006) |
| "A 75-year-old man with type 1 diabetes and history of insulin therapy for previous 3 years using only human recombinant ones was suffering from unstable glycemic control." | ( Araki, E; Chirioka, T; Matsuyoshi, A; Miyamura, N; Sakakida, M; Sakamoto, F; Shimoda, S; Taketa, K; Tsuruzoe, K, 2006) |
| "Management of type 1 diabetes is best undertaken in the context of a multidisciplinary health team and requires continuing attention to many aspects, including insulin administration, blood glucose monitoring, meal planning, and screening for comorbid conditions and diabetes-related complications." | ( Daneman, D, 2006) |
| "Patients had Type 1 diabetes, defined as a diagnosis made before age 36 years and with a need for continuous insulin therapy within a year of diagnosis." | ( Chaturvedi, N; Ferriss, JB; Fuller, JH; Idzior-Walus, B; Webb, D, 2006) |
| "For individuals with type 1 diabetes, this markedly increases (by 25-fold) the risk of severe hypoglycemia and is a major limitation to optimal insulin therapy." | ( Cheng, H; Fan, X; McCrimmon, RJ; McNay, EC; Routh, VH; Sherwin, RS; Song, Z; Weikart-Yeckel, C, 2006) |
| "Insulin therapy is essential for type 1 diabetes treatment." | ( Ceponis, J; Varanauskaite, I; Varanauskiene, E, 2006) |
| "A total of 24 consecutive patients with type 1 diabetes mellitus had been treated by SPK transplantation." | ( Aoun, M; Beaudreuil, S; Benoit, G; Charpentier, B; Cheisson, G; Duranteau, J; Durrbach, A; Eschewege, P; Hamoudi, Y; Noel, C, 2007) |
| "Nineteen patients with type 1 diabetes and metabolic instability received islet transplantation alone and immunosuppressive therapy according to the Edmonton protocol." | ( Bertuzzi, F; Caumo, A; De Taddeo, F; del Maschio, A; Fiorina, P; Maffi, P; Magistretti, P; Nano, R; Pozzi, P; Secchi, A; Socci, C; Venturini, M, 2007) |
| "In a 26-week trial, 1178 patients with type 1 diabetes and treated with different basal-bolus regimens were randomized to receive insulin glargine once daily at dinner (n=589) or at bedtime (n=589) while continuing their previous prandial insulin (FAA: 75%; RHI: 25% of patients)." | ( Blayo, A; Brun, JM; Grimaldi, A; Halimi, S; Vialettes, B, 2007) |
| "In both IDDM and NIDDM diabetic neuropathic patients, chronic sildenafil treatment exhibited a significant decrease in total sperm output and sperm concentration (p<0." | ( Ali, ST; Rakkah, NI, 2007) |
| "Twelve pubertal adolescents with type 1 diabetes and initially on NPH insulin were studied during 12 weeks of intensified treatment with glargine." | ( Bang, P; Carlsson-Skwirut, C; Ekström, K; Ortqvist, E; Salemyr, J; Zachrisson, I, 2007) |
| "Patients with type 1 diabetes treated with human or analogue insulin have different insulin demands if their renal function is decreased." | ( Dreyhaupt, J; Hasslacher, C; Raupp, D; Vogt, C, 2007) |
| "Forty-two patients with new-onset type 1 diabetes were started on standard treatment." | ( Hassan, K; Heptulla, RA; Johnson, SE; Rodriguez, LM; Tadlock, S, 2008) |
| "A 51-year-old man developed type 1 diabetes mellitus following 24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin for chronic hepatitis C." | ( Beppu, T; Fuke, H; Ito, K; Shiraki, K; Sugimoto, K; Takei, Y; Tanaka, J; Yamamoto, N; Yoneda, K, 2008) |
| "The majority of type 1 diabetes patients in Denmark are treated with the flexible basal-bolus insulin regimen." | ( Hermansen, K; Lammert, M; Palmer, AJ, 2008) |
| "To report a case of type 1 diabetes mellitus (T1DM) in a child with phenobarbital hypersensitivity syndrome with an emphasis on the clinical presentation, diagnostic modalities and treatment options." | ( Fu, JF; Liang, L; Zou, CC, 2008) |
| "Hyperglycemia in type 1 diabetes and treatment of proximal tubular epithelial cells with high glucose leads to phosphorylation/inactivation of tuberin and downregulation of OGG1 via a redox-dependent activation of Akt in renal tubular epithelial cells." | ( Abboud, HE; Gorin, Y; Habib, SL; Simone, S; Velagapudi, C, 2008) |
| "In the nine participants with type 1 diabetes, treatment had no effect on any of the three indicators used to assess hyperglycaemia." | ( Brownlee, M; Du, X; Edelstein, D, 2008) |
| "She was known to have type 1 diabetes mellitus, previous Hashimoto's thyroiditis, rheumatoid arthritis treated with leflunomide and drug- treated arterial hypertension." | ( Berges, W; Donner, P; Gugenberger, C; Naami, A, 2008) |
| "A 28-year-old woman with type 1 diabetes on insulin therapy developed left oculomotor nerve palsy in the fourth month of pregnancy." | ( Kuzuhara, S; Nakano, C; Sasaki, R; Shindo, A; Sugiyama, T; Taniguchi, A, 2008) |
| "A total of 17% of women with type 1 diabetes were treated for thyroid disorder during pregnancy." | ( Damm, P; Mathiesen, ER; Nielsen, LR; Rasmussen, AK; Vestgaard, M, 2008) |
| "Subjects with the diagnosis of latent autoimmune diabetes in adults (LADA) are more prone to need insulin treatment than those with type 2 diabetes." | ( Grill, V; Midthjell, K; Nilsen, TI; Radtke, MA, 2009) |
| "Studies of animals with spontaneous autoimmune diabetes have revealed that autoreactive T cells that mediate islet beta cell destruction can be manipulated by the administration of Th(2) cytokines." | ( Hong, H; Lee, E; Lee, S; Lim, M; Park, L; Park, Y; Shin, G, 2008) |
| "A total of 16 patients with type 1 diabetes receiving treatment with either CSII (eight patients) or MDI (eight patients), all with HbA1c levels < 7%, wore a continuous glucose monitoring system sensor for 3 days to compare the number, duration, timing and severity of hyperglycaemic and hypoglycaemic episodes." | ( Chervoneva, I; Hipszer, B; Jabbour, S; Joseph, J; Li, Y; Marco, C; Padron-Massara, L; Rosenberg, D; Simon, B; Treat, V, 2008) |
| "Thirteen adolescents with type 1 diabetes on insulin pump therapy participated in a randomized, controlled, crossover design study comparing continuous sc insulin monotherapy (part A) vs." | ( Haymond, MW; Heptulla, RA; Mason, KJ; Rodriguez, LM, 2009) |
| "We previously showed that SEA prevents type 1 diabetes in NOD mice and that splenocytes from SEA-treated mice have reduced ability to transfer diabetes to NOD." | ( Burton, O; Cooke, A; Dunne, DW; Jones, FM; Miller, N; Zaccone, P, 2009) |
| "People with type 1 diabetes on NPH-based insulin therapy were randomized to CSII or glargine-based MDI (both otherwise using lispro) and followed for 24 weeks in an equivalence design." | ( Bolli, GB; Home, PD; Kerr, D; Selam, JL; Sola-Gazagnes, A; Thomas, R; Torlone, E; Vitacolonna, E, 2009) |
| "In unselected people with type 1 diabetes naïve to CSII or insulin glargine, glycemic control is no better with the more expensive CSII therapy compared with glargine-based MDI therapy." | ( Bolli, GB; Home, PD; Kerr, D; Selam, JL; Sola-Gazagnes, A; Thomas, R; Torlone, E; Vitacolonna, E, 2009) |
| "In children with type 1 diabetes, vitamin D treatment produces moderate protective effects on residual beta-cell function and has proven to be safe." | ( Huang, G; Lei, M; Li, X; Liao, L; Lin, J; Wang, X; Yan, X; Zhou, Z, 2009) |
| "In contrast, in patients with type 1 diabetes (T1DM), information about the effect of metformin treatment on lipidaemia is limited." | ( Alibegovic, AC; Astrup, AS; Frandsen, M; Hovind, P; Jacobsen, PK; Lund, SS; Parving, HH; Parving, I; Pietraszek, L; Rossing, P; Tarnow, L; Vaag, AA, 2009) |
| "In alloxan-treated mice (a model of type 1 diabetes), drugs were administered orally once daily for 6 days post-alloxan treatment." | ( Jiang, J; Larrick, JW; Wang, Y; Yu, P; Zeng, X; Zhang, Z, 2009) |
| "Hypoglycemia in young children with type 1 diabetes is an acute complication of intensive insulin therapy and is commonly observed in the absence of signs or symptoms." | ( Beck, R; Becker, DM; Buckingham, B; Fiallo-Scharer, R; Kollman, C; Mauras, N; Ruedy, K; Singh, R; Steffes, M; Tamborlane, W; Tsalikian, E; Weinzimer, S; Xing, D, 2009) |
| "Patients with type 1 diabetes require intensive insulin therapy for optimal glycemic control." | ( Berclaz, PY; Ferguson, JA; Gao, H; Garg, SK; Gates, JR; Mathieu, C; Rais, N; Tobian, JA; Webb, DM, 2009) |
| "In patients with long-standing type 1 diabetes, we investigated whether improved beta-cell function can be achieved by combining intensive insulin therapy with agents that may 1) promote beta-cell growth and/or limit beta-cell apoptosis and 2) weaken the anti-beta-cell autoimmunity." | ( Baron, A; Brooks-Worrell, B; Chen, K; Digon, BJ; Dosch, HM; Harlan, DM; Nelson, P; Palmer, JP; Ring, M; Rother, KI; Spain, LM; Wesley, RA, 2009) |
| "Forty-eight type 1 diabetes patients were divided into three groups according to their basal insulin therapy (continuous subcutaneous insulin infusion [CSII], insulin glargine, NPH insulin)." | ( Amemiya, S; Cho, H; Kobayashi, K; Mitsui, Y; Mochizuki, M; Nagamine, K; Nakazawa, S; Ohyama, K; Saitou, T; Yagasaki, H, 2010) |
| "Protection from type 1 diabetes (T1D), a T helper type 1 (Th1)-mediated disease, is achievable in non-obese diabetic (NOD) mice by treatment with alpha-galactosylceramide (alpha-GalCer) glycolipids that stimulate CD1d-restricted invariant natural killer T (iNK T) cells." | ( Besra, GS; Blumenfeld, H; Delovitch, TL; Ly, D; Porcelli, SA; Rubin, B; Tohn, R; Veerapen, N, 2010) |
| "The Adolescent type 1 Diabetes cardio-renal Intervention Trial (AdDIT) is a multi-center, randomized, double-blind, placebo-controlled trial of ACEI and Statin therapy in adolescents with type 1 diabetes." | ( , 2009) |
| "16 adult patients with type 1 diabetes (10 male) on intensive insulin therapy participated in this prospective intervention study." | ( Lehmann, R; Sprenger, M; Uthoff, H; Wiesli, P, 2010) |
| "Insulin replacement therapy in type 1 diabetes mellitus (T1DM) is nonphysiologic." | ( Lebovitz, HE, 2010) |
| "ILPS-treated patients with Type 1 diabetes achieved similar glycaemic control as insulin detemir-treated patients after 32 weeks." | ( Chacra, AR; Chan, J; Giaconia, J; Ilag, LL; Kipnes, M; Sarwat, S, 2010) |
| "We induced type 1 diabetes using streptozocin in 8-week-old Sprague-Dawley rats, divided them into two groups-a thalidomide treatment group (DM-T, n = 15) and a non-treatment group (DM-N, n = 15)-and compared them with a normal control (n = 10)." | ( Chang, HJ; Chang, SA; Kim, DH; Kim, HK; Kim, HN; Kim, YJ; Lee, HW; Park, YB; Sohn, DW, 2010) |
| "We report a case of type 1 diabetes onset and recurrence of Graves' disease during pegylated interferon (PEG-IFN)-alpha plus ribavirin treatment for chronic hepatitis C." | ( Fujioka, T; Honda, M; Koyama, K; Matsuno, H; Ogawa, M; Shimokawa, K; Yoshizaki, T, 2010) |
| "The optimal treatment of latent autoimmune diabetes in adults (LADA) is not established." | ( Landin-Olsson, M; Petersson, C; Thorgeirsson, H; Thunander, M; Törn, C, 2011) |
| "After initiation of treatment in Type 1 diabetes, a period with lower insulin requirement often follows, reflecting increased insulin sensitivity and improved insulin secretion." | ( Arnqvist, H; Berne, C; Björk, E; Bolinder, J; Karlsson, FA; Nyström, L; Schölin, A, 2011) |
| "In the NOD mouse model of type 1 diabetes, oral or nasal administration of insulin induces immune tolerance to insulin and protects against autoimmune diabetes." | ( Butler, J; Colman, PG; Fourlanos, S; Gellert, SA; Harrison, LC; Mallone, R; Martinuzzi, E; Perry, C, 2011) |
| "Forty-five patients with Type 1 diabetes and 71 healthy control subjects, divided into three age groups (18-30, 31-45 and 46-60 years old), underwent assessment of vascular reactivity based on ultrasound examination of a brachial artery after nitric oxide donor administration." | ( Czupryniak, L; Grzelak, P; Majos, A; Olszycki, M; Stefańczyk, L, 2011) |
| "Subjects with type 1 diabetes were allocated to one of three treatment orders-GLU-ASP-LIS, ASP-LIS-GLU, or LIS-GLU-ASP-with each insulin used for 13 weeks." | ( Bode, BW; Charpentier, G; DeVries, JH; Sert-Langeron, C; van Bon, AC, 2011) |
| "In 96 participants with type 1 diabetes and 40 age-matched healthy controls, we measured BRS (average of six different standard methods), oxygen saturation, end-tidal carbon dioxide and ventilation changes during spontaneous and controlled breathing at 15 and six breaths/min, in normoxia and during 5 l/min oxygen administration." | ( Bernardi, L; Forsblom, C; Groop, PH; Mäkinen, VP; Rosengård-Bärlund, M; Sandelin, A, 2011) |
| "Autoimmune type 1 diabetes (T1D) development in the inbred NOD mouse strain can be accelerated by vitamin D insufficiency or suppressed by chronic treatment with high levels of 1α,25-dihydroxyvitamin D(3)." | ( Driver, JP; Gysemans, C; Lamont, DJ; Mathieu, C; Serreze, DV, 2011) |
| "Prevention and treatment of type 1 diabetes is hampered by the fact that the key environmental trigger(s) of the disease is still unknown." | ( Barbeau, WE, 2012) |
| "Ten patients with type 1 diabetes treated with continuous subcutaneous insulin infusion underwent a standardized protocol on three different occasions: 40 g carbohydrate breakfast followed 2 h later by 30 min of moderate-intensity exercise, followed 1." | ( DeVries, JH; Hoekstra, JB; Jonker, LD; Koebrugge, R; Koops, R; Van Bon, AC, 2012) |
| "Treatment of type 1 diabetes patients could be simplified if the site of subcutaneous insulin infusion could also be used for the measurement of glucose." | ( Bodenlenz, M; Korsatko, S; Lindpointner, S; Pieber, TR; Regittnig, W; Tutkur, D, 2013) |
| "We investigated whether TPL treatment prevents autoimmune diabetes in nonobese diabetic (NOD) mice and prolongs the survival of islet grafts against autoimmune attack or allograft rejection." | ( Chen, TW; Chen, YW; Chien, MW; Chu, CC; Chu, CH; Huang, SH; Lin, GJ; Sytwu, HK; Yu, JC, 2013) |
| "Patients with long-standing type 1 diabetes can achieve weight loss and improved glycemic control on less insulin without an increase in hypoglycemia when liraglutide is added to insulin therapy." | ( Clark, GO; Harrison, LB; Lingvay, I; Mora, PF, 2013) |
| "We confirmed that fetuses of type 1 diabetes or insulin-treated gestational diabetes pregnancies experience chronic hypoxia as reflected by increased EPO concentrations in AF near term." | ( Andersson, S; Arduini, A; Asensi, MA; Cubells, E; Escobar, J; Sastre, J; Stefanovic, V; Teramo, K; Vento, M, 2013) |
| "Tight glycemic control in type 1 diabetes during pregnancy using insulin therapy together with folic acid supplementation are partially able to prevent diabetic embryopathy; however, the protection is not complete and additional interventions are needed." | ( Dipette, DJ; Kumar, A; Lavoie, HA; Singh, CK; Singh, US, 2013) |
| "We recruited 25 patients with type 1 diabetes (mean age 51 ± 10 years, mean disease duration 26 ± 13 years) and 31 insulin-treated type 2 diabetic patients (mean age 66 ± 8 years, mean disease duration 19 ± 9 years), who received sitagliptin with metformin as a fixed-dose combination (50/1000 mg once or twice daily) or sitagliptin (100 mg once daily, if intolerant to metformin) in addition to ongoing insulin therapy for 46 ± 19 weeks and 56 ± 14 weeks, respectively." | ( Bartola, LD; Giampietro, C; Giampietro, O; Masoni, MC; Matteucci, E, 2013) |
| "Management of type 1 diabetes essentially relies upon intensive insulin therapy adjusted according to careful home blood glucose monitoring." | ( Scheen, AJ, 2013) |
| "We report a case of type 1 diabetes mellitus during pegylated interferon and ribavirin treatment for chronic hepatitis C, in a young man previously diagnosed with Hashimoto's thyroiditis and vitiligo." | ( Arama, V; Popescu, C; Popescu, GA, 2013) |
| "In patients with type 1 diabetes and hypoglycemia unawareness, treatment with EPO is associated with a beneficial effect on cognitive function in a complex reaction time task assessing sustained attention/working memory." | ( Dela, F; Faber, J; Holst, JJ; Kjær, TW; Kristensen, PL; Olsen, NV; Pedersen-Bjergaard, U; Tarnow, L; Thorsteinsson, B, 2013) |
| "The main goal of the therapy for type 1 diabetes has long been physiological mimicry of normal insulin secretion based on monitoring which requires considerable effort and understanding of the underlying physiology." | ( Farhy, LS; McCall, AL, 2013) |
| "In this cohort of type 1 diabetes patients with mild-to-moderate CAN, a combination antioxidant treatment regimen did not prevent progression of CAN, had no beneficial effects on myocardial perfusion or DPN, and may have been detrimental." | ( Brown, MB; Feldman, EL; Mehta, M; Plunkett, CD; Pop-Busui, R; Raffel, DM; Stevens, MJ; White, EA, 2013) |
| "Some menopausal women with type 1 diabetes are treated with hormone replacement therapy (HRT) but the effects of this treatment have, to date, not been established." | ( Adamson, KA; Chisholm, J; Kilbride, L; Mackay, L, 2013) |
| "Then, sixty newly diagnosed adult type 1 diabetes patients will be randomized to either conventional treatment or exercise, stratified on beta cell function and fitness." | ( Andrews, R; Daley, A; Dowswell, G; Greenfield, S; Holder, R; Jackson, N; Kennedy, A; Lascar, N; Narendran, P; Stokes, K; Thompson, D, 2013) |
| "In addition, monotherapy of type 1 diabetes in youth with insulin does not achieve HbA1c targets in the majority of youth despite the use of rapid-acting insulin analogues, insulin pump therapy, and continuous glucose monitoring." | ( Silverstein, J; Wood, JR, 2013) |
| "In rodent models of type 1 diabetes, leptin administration into brain ventricles normalizes blood glucose at doses that have no effect when given peripherally." | ( Damian, V; Dorfman, MD; Guyenet, SJ; Matsen, ME; Meek, TH; Morton, GJ; Nguyen, HT; Taborsky, GJ, 2013) |
| "The optimal treatment of latent autoimmune diabetes in adults (LADA) is not established." | ( Otto-Buczkowska, E, 2013) |
| "A total of 44 type 1 diabetes mellitus patients were randomised into the treatment group [n = 22; received a low-dose combination of fluvastatin (10 mg daily) and valsartan (20 mg daily)] and the control group (n = 22; received placebo), both for 30 days." | ( Boncelj, M; Eržen, B; Janež, A; Janić, M; Kanc, K; Lunder, M; Šabović, M; Savić, V, 2013) |
| "A total of 33 obese patients with type 1 diabetes treated with intensive insulin therapy were randomized into a group where metformin was added." | ( Burchardt, P; Kaczmarek, J; Marcinkaniec, J; Naskręt, D; Tabaczewski, P; Wierusz-Wysocka, B; Wysocki, H; Zawada, A, 2013) |
| "Currently, patients with type 1 diabetes decide on the amount of insulin to administer based on several factors, including current plasma glucose value, expected meal input, and physical activity (PA)." | ( Basu, A; Carter, RE; Hinshaw, L; Kudva, YC; Levine, JA; Lingineni, R; Manohar, C; McCrady-Spitzer, SK; O'Keeffe, DT, 2013) |
| "Patients with type 1 diabetes, particularly those with residual β-cell function, may also respond to treatment, but the acute metabolic effects of GLP-1 analogs on these patients in reaction to both oral and intravenous glucose challenges are not well understood." | ( Ghazi, T; Herold, KC; Rink, L; Sherr, JL, 2014) |
| "Betatrophin treatment in type 1 diabetes would therefore probably not be successful without the use of supraphysiological doses or a combination with immune regulatory treatment." | ( Carlsson, PO; Espes, D; Lau, J, 2014) |
| "People with type 1 diabetes must monitor their blood glucose throughout the day using a glucose meter or a continuous glucose monitor, calculate how much insulin is needed to maintain normal blood glucose levels, and administer the insulin dose by pen injection or insulin pump infusion into the subcutaneous tissue." | ( Schmidt, S, 2013) |
| "Islet transplantation to treat type 1 diabetes (T1D) has shown varied long-term success, due in part to insufficient blood supply to maintain the islets." | ( Korbutt, GS; McBane, JE; McEwan, KA; Padavan, DT; Suuronen, EJ; Vulesevic, B, 2013) |
| "Sixteen pump-treated patients with type 1 diabetes received 48 h of closed-loop therapy with a telemonitored insulin- and glucagon-delivering closed-loop system and 48 h of patient-managed open-loop therapy." | ( DeVries, JH; Hoekstra, JB; Koebrugge, R; Koops, R; Luijf, YM; van Bon, AC, 2014) |
| "Pharmacotherapy of type 1 diabetes (T1D) is mainly restricted to insulin treatment." | ( Ludvigsson, J, 2014) |
| "A 14-year-old girl with type 1 diabetes mellitus occurred with dental pain, facial swelling, ecchymosis and left eye decreased visual acuity, unresponsive to antibiotic therapy." | ( Costantino, F; Di Biasi, C; di Coste, A; Duse, M; Ernesti, I; Melengu, T; Savastano, V; Schiavi, L; Tarani, L, 2013) |
| "Therapeutic options for treatment of type 1 diabetes (T1D) are still missing." | ( Imam, S; Jaume, JC; Mirmira, RG, 2014) |
| "We employed two accelerated autoimmune diabetes models: (i) cyclophosphamide (CYP) administration to non-obese diabetic (NOD) mice and (ii) adoptive transfer of diabetogenic splenocytes into NODscid mice." | ( Antunica Noguerol, M; Barcala Tabarrozzi, AE; Castro, CN; Dewey, RA; Gimeno, ML; Liberman, AC; Paz, DA; Perone, MJ; Winnewisser, J, 2014) |
| "Available anti-hyperglycemic therapy in type 1 diabetes (T1DM) is currently restricted to insulin, pramlintide, and pancreas or islet cell transplantation." | ( Davis, SN; Lamos, EM; Younk, LM, 2014) |
| "The current treatment for type 1 diabetes, insulin monotherapy, is suboptimal to fully stabilize glycemia, potentially leading to this subfertility." | ( Bertschinger, A; Chi, M; Drury, A; Esakky, P; Moley, KH; Schoeller, EL, 2014) |
| "Subjects with type 1 diabetes (T1DM) on insulin pump therapy were recruited to participate in a 27-hour hospitalized admission on 3 occasions (2-4 weeks apart) and placed on the insulin delivery via CL system in random order to receive (1) insulin alone (control), (2) exenatide 2." | ( Cantwell, M; Heptulla, RA; Ramchandani, N; Renukuntla, VS; Trast, J, 2014) |
| "Children with type 1 diabetes from the PRESCHOOL study, aged 2-6 yr, were treated with insulin glargine for 24 wk (n = 62)." | ( Becker, RH; Danne, T; Philotheou, A; Ping, L, 2015) |
| "Axonal function in type 1 diabetes is maintained within normal limits in patients treated with continuous subcutaneous insulin infusion and not with multiple daily insulin injections." | ( Arnold, R; Kiernan, MC; Krishnan, AV; Kwai, N; Lin, CS; Poynten, AM, 2015) |
| "Intensive insulin treatment in type 1 diabetes reduces the incidence and slows the progression of microvascular and macrovascular complications; however, it is associated with an increased risk of hypoglycaemia and weight gain." | ( Holst, JJ; Madsbad, S; Nørgaard, K; Ranjan, A; Reiband, HK; Schmidt, S, 2015) |
| "The identification of type 1 diabetes in diabetic subjects receiving insulin therapy is sometimes difficult." | ( Chen, YC; Hsieh, SH; Huang, YY; Li, HY; Lin, CH; Liu, SW, 2015) |
| "People with type 1 diabetes (T1D) must administer insulin exogenously due to the destruction of their pancreatic β-cells." | ( Chen, C; Liu, Y; Medawala, W; Spence, DM; Summers, S, 2015) |
| "Long-term data of patients with type 1 diabetes mellitus (T1D) after simultaneous islet-kidney (SIK) or islet-after-kidney transplantation (IAK) are rare and have never been compared to intensified insulin therapy (IIT)." | ( Ajdler-Schaeffler, E; Brändle, M; Gerber, PA; Kron, P; Lehmann, R; Locher, R; Oberkofler, C; Spinas, GA; Tschopp, O; Zuellig, RA, 2015) |
| "Insulin therapy in type 1 diabetes still provides suboptimal outcomes." | ( Bergenstal, RM; Bolli, GB; Espinasse, M; Home, PD; Riddle, MC; Rojeski, M; Ziemen, M, 2015) |
| "Patients with type 1 diabetes, who had received a kidney transplant previously, were treated with alemtuzumab as induction therapy for their first islet transplantation and basiliximab induction therapy for subsequent islet transplantations." | ( Bouwsma, H; Braat, AE; de Fijter, JW; de Koning, EJ; Dubbeld, J; Engelse, MA; Nijhoff, MF; Rabelink, TJ; Ringers, J; Roelen, DL; Spijker, HS; van der Boog, PJ; van Erkel, AR, 2016) |
| "Patients aged 18 years or older with type 1 diabetes, insufficient glycaemic control (HbA1c >8% [64 mmol/mol]), and overweight (BMI >25 kg/m(2)) were randomly assigned (1:1) to receive insulin treatment plus either liraglutide or placebo (saline solution) by subcutaneous injection once per day." | ( Almdal, T; Andersen, HU; Dejgaard, TF; Frandsen, CS; Hansen, TS; Holst, JJ; Jensen, AK; Jensen, T; Knop, FK; Madsbad, S; Pedersen-Bjergaard, U; Tarnow, L; Urhammer, S, 2016) |
| "In patients with type 1 diabetes, overweight, and insufficient glycaemic control, the reduction in HbA1c did not differ between insulin plus placebo and insulin plus liraglutide treatment." | ( Almdal, T; Andersen, HU; Dejgaard, TF; Frandsen, CS; Hansen, TS; Holst, JJ; Jensen, AK; Jensen, T; Knop, FK; Madsbad, S; Pedersen-Bjergaard, U; Tarnow, L; Urhammer, S, 2016) |
| "Insulin therapy is essential for type 1 diabetes but hyperinsulinemia potentially exacerbates PCOS through hyperandrogenism." | ( Hirose, T; Kitamura, M; Kumashiro, N; Rikitake, T; Saegusa, M; Shigiyama, F; Uchino, H; Usui, S, 2016) |
| "The current treatment of type 1 diabetes consists of insulin administration." | ( Cevik, A; Gurol, AO; Gurol, SD; Kasapoglu, P; Kucuk, M; Kucuksezer, UC; Okten-Kursun, A; Suzergoz, F; Tutuncu, Y; Yentur, SP; Yilmaz, MT, 2016) |
| "Twelve adults with type 1 diabetes receiving treatment with insulin pumps received subcutaneous doses of 75, 150, and 300 μg of nonaqueous glucagon." | ( Cummins, MJ; Haymond, MW; Kinzell, J; McKay, S; Newswanger, B; Prestrelski, S; Redondo, MJ, 2016) |
| "Many persons with type 1 diabetes do not achieve glycemic targets, why new treatments, complementary to insulin, are of interest." | ( Dejgaard, TF; Frandsen, CS; Holst, JJ; Madsbad, S, 2016) |
| "Insulin treatment of individuals with type 1 diabetes has shortcomings and many patients do not achieve glycaemic and metabolic targets." | ( Dejgaard, TF; Frandsen, CS; Madsbad, S, 2016) |
| "Gold standard type 1 diabetes was defined as continuous insulin treatment within 3 years of diagnosis and absolute insulin deficiency (UCPCR<0." | ( Fox, C; Hattersley, AT; Hope, SV; Jones, AG; Khunti, K; King, SM; Knight, BA; Oram, RA; Shepherd, M; Shields, BM; Wienand-Barnett, S, 2016) |
| "In the present study, 93 type 1 diabetes patients and 135 type 2 diabetes patients treated with insulin glargine or detemir were switched from their basal insulin to insulin degludec." | ( Araki, E; Fujisawa, K; Fukuda, K; Fukunaga, M; Ichimori, S; Matsuo, Y; Motoshima, H; Noda, H; Okubo, M; Sato, M; Sekigami, T; Shimoda, S; Yoshimura, R, 2016) |
| "In patients with type 1 diabetes, treatment with BIL compared with GL for 52 weeks resulted in a lower HbA1c, more patients with HbA1c levels <7%, and reduced nocturnal hypoglycaemia, but more total hypoglycaemia and injection site reactions and higher triglyceride and ALT levels." | ( Antalis, CJ; Bastyr, EJ; Bergenstal, RM; Franek, E; Hartman, ML; Jacober, SJ; Lunt, H; Mou, J; Qu, Y; Rosilio, M; Travert, F, 2016) |
| "Seventeen patients with type 1 diabetes who received pancreatic islet transplantation and anti-CD25 mAb as induction therapy were studied." | ( Gürth, CM; Monti, P; Pellegrini, S; Piemonti, L; Sizzano, F; Sordi, V; Vignali, D, 2016) |
| "Eight individuals with longstanding type 1 diabetes and ten sex-, age- and BMI-matched healthy controls underwent dynamic positron emission tomography scanning with (15)O-labelled water before and after intravenous administration of glucose." | ( Ahlström, H; Carlbom, L; Carlsson, PO; Eriksson, O; Espes, D; Jansson, L; Johansson, L; Korsgren, O; Lubberink, M, 2016) |
| "In random order, 21 adults with type 1 diabetes (T1D) underwent three 22-hour experimental sessions: AP with exercise dosing adjustment (APX); AP with no exercise dosing adjustment (APN); and sensor-augmented pump (SAP) therapy." | ( Branigan, D; Castle, JR; Condon, J; Edwards, C; El Youssef, J; Jacobs, PG; Jones, M; Kuehl, K; Leitschuh, J; Preiser, N; Rajhbeharrysingh, U; Ramsey, K; Reddy, R; Resalat, N, 2016) |
| "In patients with type 1 diabetes, treatment with BIL compared to GL for 26 weeks was associated with lower HbA1c, less nocturnal hypoglycemia, lower glucose variability and weight loss." | ( Bastyr, EJ; Dreyer, M; Garg, S; Hartman, ML; Jacober, SJ; Jinnouchi, H; Mou, J; Qu, Y; Rosilio, M, 2016) |
| "In vivo, type 1 diabetes mellitus was induced in mice by administering streptozotocin." | ( Chen, X; Du, Z; Liang, E; Liu, X; Lu, J; Song, X; Zhang, M; Zhang, Y; Zhao, Y, 2016) |
| "Twenty-three type 1 diabetes patients without overt CVD were treated with metformin for 8 weeks (treatment group-TG)." | ( Ahmed, FW; Glanville, M; Narayanan, K; Razvi, S; Rider, R; Weaver, JU, 2016) |
| "A 29-year-old, Caucasian woman with type 1 diabetes and hepatitis C virus infection was referred with hyperthyroidism, while she was at 17 weeks of a planned 24-week course of interferon alpha therapy." | ( Bajwa, H; Buch, HN; Gill, G; Strouhal, P, 2016) |
| "Ten patients with insulin pump-treated type 1 diabetes randomly completed 1 week of the HCD (≥250 g/day) and 1 week of the LCD (≤50 g/day)." | ( Clausen, TR; Damm-Frydenberg, C; Holst, JJ; Madsbad, S; Nørgaard, K; Ranjan, A; Schmidt, S; Steineck, I, 2017) |
| "Long-acting insulin analogues for type 1 diabetes (T1D) treatment have been available on the Brazilian market since 2002." | ( Laranjeira, FO; Pereira, MG; Silva, EN, 2016) |
| "Latent autoimmune diabetes in adults (LADA) usually refers to GAD65 autoantibodies (GADAb)-positive diabetes with onset after 35 years of age and no insulin treatment within the first 6 months after diagnosis." | ( Al-Majdoub, M; Ali, A; Groop, L; Rosengren, AH; Spégel, P; Storm, P, 2017) |
| "Although most women with type 1 diabetes experience the normal transition to menopause, there is little information about the impact of hormone replacement therapy on their glycemic profiles." | ( Hishiki, M; Nakayama, M; Ogasawara, J; Sorimachi, E; Tanaka, S, 2017) |
| "Stem cell-based therapy for type 1 diabetes would benefit from implementation of a cell purification step at the pancreatic endoderm stage." | ( Ameri, J; Borup, R; Prawiro, C; Ramond, C; Schachter, KA; Scharfmann, R; Semb, H, 2017) |
| "In patients with type 1 diabetes treated with BIL, but not glargine, small LDL and medium and large VLDL subclass concentrations increased from baseline." | ( Antalis, CJ; Cariou, B; Connelly, MA; Hoogwerf, BJ; Ivanyi, T; Orchard, TJ; Otvos, JD; Zhang, S, 2017) |
| "Therapy must be adapted for people with type 1 diabetes to avoid exercise-induced hypoglycemia caused by increased exercise-related glucose uptake into muscles." | ( Bracken, RM; Eckstein, ML; Groeschl, W; Hofmann, P; Koehler, G; Moser, O; Mueller, A; Pieber, TR; Tschakert, G, 2017) |
| "Among patients with type 1 diabetes and at least 1 risk factor for hypoglycemia, 32 weeks' treatment with insulin degludec vs insulin glargine U100 resulted in a reduced rate of overall symptomatic hypoglycemic episodes." | ( Bailey, TS; Gerety, G; Gumprecht, J; Hansen, CT; Lane, W; Nielsen, TSS; Philis-Tsimikas, A; Warren, M, 2017) |
| "Immunotherapy for type 1 diabetes (T1D) has previously focused on suppressing the autoimmune response against pancreatic beta cells to preserve endogenous insulin production and regulate glucose levels." | ( Boursalian, TE; Coppieters, K; Friesen, TJ; Gibson, CB; Haase, C; Kirk, RK; Pagni, PP; Perdue, NR; Ratliff, SS; Rydén, AK; von Herrath, MG, 2017) |
| "In most patients with type 1 diabetes, adequate glycemic control is not achieved with insulin therapy alone." | ( Banks, P; Buse, JB; Danne, T; Davies, MJ; Fulcher, GR; Garg, SK; Gesty-Palmer, D; Henry, RR; Kushner, JA; Lapuerta, P; McGuire, DK; Peters, A; Pozzilli, P; Simó, R; Strumph, P, 2017) |
| "A major advancement in therapy of type 1 diabetes mellitus (T1DM) is the discovery of new treatment which avoids and even replaces the absolute requirement for injected insulin." | ( Al-Salami, H; Goločorbin-Kon, S; Mikov, M; Pavlović, N; Stanimirov, B; Stankov, K; Đanić, M, 2018) |
| "Twenty-nine adults with type 1 diabetes who had metformin added to their insulin therapy for 12 months were compared with 29 adults with type 1 diabetes who remained on insulin-alone therapy." | ( Beysel, S; Cakal, E; Caliskan, M; Kizilgul, M; Ucan, B; Unsal, IO, 2018) |
| "Fulminant type 1 diabetes mellitus was diagnosed, and she was immediately treated with multiple daily injections of insulin." | ( Arihara, Z; Niitsuma, S; Sakurai, K; Sato, R; Takahashi, K, 2018) |
| "Therapy for type 1 diabetes (T1D) is mainly restricted to insulin treatment." | ( Naciu, AM; Pozzilli, P, 2018) |
| "All individuals with type 1 diabetes (T1D) and a significant majority of those with T2D will ultimately require insulin therapy." | ( Daisy, B; Logan, T, 2018) |
| "In addition, type 1 diabetes mellitus (T1DM) is also characterized by a proinflammatory state and by requiring insulin exogenous treatment." | ( Álvarez, ML; Arboatti, AS; Carnovale, CE; Francés, DEA; Lambertucci, F; Monti, J; Pisani, G; Ronco, MT; Sedlmeier, MG, 2018) |
| "CONCLUSIONS In patients with type 1 diabetes and excess body fat, treated with intensive functional insulin therapy, the addition of metformin improves metabolic control of diabetes at 6 months." | ( Burchardt, P; Grzymisławski, M; Naskręt, D; Niedźwiecki, P; Piłaciński, S; Wierusz-Wysocka, B; Zawada, A; Zozulińska-Ziółkiewicz, D, 2018) |
| "Persons with type 1 diabetes require intensive insulin therapy to achieve glycaemic control, but side effects, including hypoglycaemia and weight gain, may reduce treatment compliance." | ( Andersen, HU; Dejgaard, TF; Johansen, NJ; Knop, FK; Lund, A; Vilsbøll, T, 2018) |
| "Both hormones are lacking in type 1 diabetes, and postprandial glucose control using insulin therapy alone is difficult." | ( Castle, J; Han, J; Hanavan, K; Hompesch, M; Huffman, D; Nahra, R; Öhman, P; Riddle, MC; Strange, P, 2018) |
| "Patients with type 1 diabetes were stabilized on insulin pump therapy with insulin lispro before a randomized, single-masked, two-way crossover, 24-h inpatient study in which regular human insulin was administered with pramlintide or placebo using separate infusion pumps in a fixed ratio (9 μg/unit)." | ( Castle, J; Han, J; Hanavan, K; Hompesch, M; Huffman, D; Nahra, R; Öhman, P; Riddle, MC; Strange, P, 2018) |
| "Mitochondria play a role in type 1 diabetes (T1D) particularly in the treatment and prevention of disorder consequences." | ( Crulli, M; Gallo, A; Lapolla, A; Nuti, F; Papini, AM; Peroni, E; Piarulli, F; Real-Fernandez, F; Rentier, C; Rossi, G; Rovero, P; Traldi, P, 2018) |
| "Current treatment of type 1 diabetes mellitus (T1DM) does not always achieve metabolic control because, among other things, the ocurrence of hypoglycemic events associated to insulin use." | ( Ares, J; Cacho, L; Delgado, E; García Urruzola, F; Manjón, L; Menéndez Torre, EL; Pujante Alarcón, P; Rodríguez Escobedo, R; Sanchez Ragnarson, C, 2019) |
| "In patients with type 1 diabetes, treatment with dapagliflozin over 24 weeks improved time in range, mean glucose, and glycemic variability without increasing the time spent in the range indicating hypoglycemia." | ( Dandona, P; Hansen, L; Langkilde, AM; Lind, M; Mathieu, C; Oron, T; Phillip, M; Thorén, F; Xu, J, 2019) |
| "We assessed the characteristics of type 1 diabetes defined by rapid insulin requirement (within 3 years of diagnosis) and severe endogenous insulin deficiency (non-fasting C-peptide <200 pmol/l) in 583 participants with insulin-treated diabetes, diagnosed after age 30, from the Diabetes Alliance for Research in England (DARE) population cohort." | ( Hattersley, AT; Hill, AV; Jones, AG; Lynam, AL; McDonald, TJ; Oram, RA; Shields, BM; Thomas, NJ; Weedon, MN, 2019) |
| "Many patients with type 1 diabetes (T1D) struggle to achieve glycaemic control and experience significant fluctuations in glucose concentrations, despite insulin treatment." | ( Boeder, S; Edelman, SV, 2019) |
| "The key to efficiently treat type 1 diabetes is to accurately inject insulin according to the blood glucose levels." | ( Chen, M; Dai, W; Guo, Z; Lei, Y; Liu, S; Shi, K; Tan, D; Wang, X; Wu, M; Xue, L; Zhang, Y, 2019) |
| "Sixteen children and adolescents with type 1 diabetes (T1D) had blood samples obtained, 6-12 hours into treatment, at three weeks and three months post start of treatment." | ( Artlett, CM; Blum, J; Hoffman, WH; Ikeda, T; Ishikawa, T; Tani, N, 2020) |
| "Our results show that type 1 diabetes, at early stages, induces mild changes in the NPY system in the hippocampus that were counteracted by sitagliptin treatment." | ( Ambrósio, AF; Brudzewsky, D; Campos, EJ; Martins, J; Woldbye, DPD, 2020) |
| "Adolescents with type 1 diabetes treated for DKA from January 2015 through December 2018 who switched basal insulin from IGlarU100 to IDeg were eligible for analysis." | ( Schmitt, J; Scott, ML, 2019) |
| "An animal model of type 1 diabetes was created by treating rats with streptozotocin (STZ)." | ( Chen, Z; Gong, D; Liu, X; Wang, L; Yang, Y; Zhang, J, 2020) |
| "Treatment of type 1 diabetes with exogenous insulin often results in unpredictable daily glucose variability and hypoglycemia, which can be dangerous." | ( Castle, JR; Jacobs, PG; Wilson, LM, 2020) |
| "The health conditions of the rats with Type 1 diabetes were significantly enhanced after treatment with MTSE/ZnO/Ag (p < 0." | ( Abdul Raman, AA; Bayrami, A; Chae, KH; Darvishi Cheshmeh Soltani, R; Habibi-Yangjeh, A; Kang, HK; Khataee, A; Mohammadi Arvanag, F; Rahim Pouran, S; Singh, R, 2020) |
| "These findings suggested that in type 1 diabetes, dapagliflozin was effective in combination with a low dose of insulin; however, the administration of dapagliflozin alone did not achieve a significant effect." | ( Abdalla, O; Dessouki, A; Kilany, O; Sasaki, K; Sayed, N; Shimoda, M; Yoshida, T, 2020) |
| "People with type 1 diabetes who use continuous subcutaneous insulin infusion (CSII, or insulin pump therapy) often remove their pump before extended periods of exercise, but this approach might result in reduced glycaemic control and increased risk of hyperglycaemia and ketogenesis." | ( Aronson, R; Brown, RE; Li, A; McGaugh, S; Riddell, MC, 2020) |
| "Exenatide added to insulin therapy in type 1 diabetes for 26 weeks resulted in body weight loss primarily from fat mass reduction, but had no effect on biomarkers of cardiovascular disease risk." | ( Andersen, HU; Dejgaard, TF; Goetze, JP; Johansen, NJ; Knop, FK; Larsen, EL; Lund, A; Møller, HJ; Poulsen, HE; Schlüntz, C; Vilsbøll, T, 2020) |
| "Patients with type 1 diabetes (T1D) are associated with a high risk of multiple complications, so the development of T1D treatment is urgently needed." | ( Jiao, PF; Ma, XJ; Ren, GF; Xiao, LL; Yan, YS, 2020) |
| "We present the first case of autoimmune diabetes during Sintilimab treatment in a patient with unresectable HCC, accompanied by a remarkable anti-tumor effect of partial regression." | ( Bai, X; Chen, Y; Liang, T; Wen, L; Zou, X, 2020) |
| "People with type 1 diabetes (T1D) require exogenous administration of insulin, which stimulates the translocation of the GLUT4 glucose transporter to cell membranes." | ( Fletcher, D; Geiger, M; Janes, T; Karunarathne, A; Keshavarz, H; Pinger, C; Spence, D; Summers, S; Tennakoon, M; Zinn, K, 2020) |
| "The long-term insulin therapy for type 1 diabetes mellitus (T1DM) fails to achieve optimal glycemic control and avoid adverse events simultaneously." | ( Gao, W; Gao, Y; Li, YK; Liu, GJ; Ran, XW; Sun, SY, 2020) |
| "Ten adults with insulin pump-treated type 1 diabetes were included in this randomized, single-blind, two-way crossover study." | ( Holst, JJ; Laugesen, C; Nørgaard, K; Ranjan, AG; Schmidt, S, 2021) |
| "Thirty-nine adults with type 1 diabetes and polyneuropathy were randomly assigned to 26 weeks of liraglutide or placebo treatment." | ( Baek, A; Brock, B; Brock, C; Drewes, AM; Jessen, N; Meldgaard, T; Vyberg, M; Wegeberg, AM, 2021) |
| "People with type 1 diabetes mellitus (T1DM) need treatment with insulin for survival." | ( Hemmingsen, B; Metzendorf, MI; Richter, B, 2021) |
| "Patients with type 1 diabetes mellitus (T1DM) receiving insulin therapy commonly suffer from insulin-mediated hypoglycemia and require glucagon for glycemic control to achieve normal plasma glucose (PG) levels." | ( Chen, Z; Tang, G; Xu, B, 2021) |
| "A good treatment for type 1 diabetes mellitus (T1DM) requires accurate measurements of blood glucose levels." | ( Alvarez, H; Herron-Bedoya, A; Lema-Perez, L; Walteros-Leon, M, 2021) |
| "Notably, some adults with type 1 diabetes may not require insulin at diagnosis, their clinical disease can masquerade as type 2 diabetes, and the consequent misclassification may result in inappropriate treatment." | ( Buzzetti, R; Dabelea, D; Dunne, JL; Evans-Molina, C; Freund-Brown, J; Gillespie, KM; Goland, R; Jones, AG; Kacher, M; Leslie, RD; Phillips, LS; Rolandsson, O; Wardian, JL, 2021) |
| "Anti-CD20 therapy delays type 1 diabetes mellitus (T1DM) progression in both nonobese diabetic (NOD) mice and new-onset patients." | ( Chen, M; Chen, X; Wan, Q; Wei, Y; Xu, M; Zhang, Q, 2022) |
| "Twenty adults with type 1 diabetes using multiple daily injection or insulin pump therapy completed a phase 2, randomized, three-arm crossover study." | ( Laugesen, C; Nørgaard, K; Ranjan, AG; Schmidt, S, 2022) |
| "In newly diagnosed patients with type 1 diabetes, short-term LDX treatment had no appreciable effect on preserving residual beta cell function." | ( Allegretti, M; Bosi, E; Cossu, E; Daffonchio, L; Gillard, P; Giorgino, F; Goisis, G; Keymeulen, B; Linn, T; Mantelli, F; Maurizi, AR; Piemonti, L; Pozzilli, P; Rose, L; Ruffini, PA, 2022) |
| "Forty adolescents and 40 adults with type 1 diabetes aged 12-60 years old were enrolled in a double-blind, placebo-controlled, random order crossover study of 4 weeks of treatment in the morning with BCQR (titrated weekly from 0." | ( Baumgartner, AD; Gross, S; Lyon, E; Nadeau, KJ; Polsky, S; Schafer, M; Schauer, IE; Snell-Bergeon, JK; Tell, SS; Vigers, T, 2022) |
| "We report a 45-year-old male with type 1 diabetes mellitus (T1DM) treated with insulin analogues suffering from recurrent hypoglycemic coma and diabetic ketoacidosis (DKA)." | ( Cheng, L; Hu, X; Kong, Y; Ling, C; Zhang, Y, 2022) |
| "Most patients with type 1 diabetes (T1DM) do not reach the blood glucose goal with treatment of insulin." | ( Dong, L; Li, H; Li, Y; Lin, D; Lou, P; Ma, L; Wang, K; Xu, L; Zang, D, 2022) |
| "The diagnosis of type 1 diabetes mellitus was placed, and intensified insulin therapy was initiated." | ( Fousteris, E; Lygnos, D; Xenou, M; Zoupas, I, 2022) |
| "Patients with insulin-treated type 1 diabetes (T1D) are exposed to hypoglycaemia, which may be serious." | ( Lebrethon, MC; Philips, JC; Radermecker, RP; S, S, 2022) |
| "The clinical trials in adults with type 1 diabetes confirmed the efficacy of SGLT2 inhibitors as add-on therapy to insulin." | ( Battelino, T; Dovc, K; Hropot, T, 2023) |
| "A 45-year-old woman affected by type 1 diabetes mellitus was treated with kidney-pancreas transplantation in 2015, 6 years before COVID-19 infection." | ( Pitocco, D; Pontecorvi, A; Popolla, V; Rizzi, A; Tartaglione, L, 2023) |
| "There has been no case report of type 1 diabetes diagnosed 7 months after the last administration of an ICI." | ( Hatakeyama, N; Ichihara, S; Kadota, N; Kunishige, M; Machida, H; Naruse, K; Okano, Y; Shinohara, T; Takeuchi, E, 2023) |
| "There has been no case report of type 1 diabetes diagnosed 7 months after the last administration of an ICI." | ( Hatakeyama, N; Ichihara, S; Kadota, N; Kunishige, M; Machida, H; Naruse, K; Okano, Y; Shinohara, T; Takeuchi, E, 2023) |
| "There has been no case report of type 1 diabetes diagnosed 7 months after the last administration of an ICI." | ( Hatakeyama, N; Ichihara, S; Kadota, N; Kunishige, M; Machida, H; Naruse, K; Okano, Y; Shinohara, T; Takeuchi, E, 2023) |
| "Children aged 6-12 years with type 1 diabetes were allocated to receive cholecalciferol and lansoprazole (Group 1) or no treatment (Group 2)." | ( Attri, SV; Dayal, D; Gupta, VK; Reddy, R; Sachdeva, N, 2022) |
| "Children aged 6-12 years with type 1 diabetes were allocated to receive cholecalciferol and lansoprazole (Group 1) or no treatment (Group 2)." | ( Attri, SV; Dayal, D; Gupta, VK; Reddy, R; Sachdeva, N, 2022) |
| "PDR and DKD were absent in type 1 diabetes patients carrying the protective INS variant and receiving intensive insulin therapy (the current standard of clinical care) 1-5 years from their diagnosis (n = 67; mean post-diagnosis follow up of 20." | ( Kaddis, JS; Roep, BO; van Tienhoven, R; Vu, AN, 2023) |
| "Checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM) is a distinct form of autoimmune diabetes that is a rare complication of immune checkpoint inhibitor therapy." | ( Brown, DA; Carlino, MS; Clifton-Bligh, R; Gunton, JE; Menzies, AM; Sasson, SC; Tsang, V; Wu, L, 2023) |
| "Pregnant individuals with type 1 diabetes mellitus using either intravenous insulin infusion or continuation of their continuous subcutaneous insulin infusion for intrapartum insulin administration had no difference in the primary outcome of neonatal hypoglycemia." | ( Delpapa, E; Leftwich, HK; Wilkie, GL, 2023) |
| "A minority of people with type 1 diabetes have access to glucagon suggesting more could be done to better target this treatment." | ( Dover, AR; Forbes, S; Gibb, FW; Jeeyavudeen, MS; Lyall, MJ; Stimson, RH; Strachan, MWJ; Wright, RJ, 2023) |
| "Treatment of type 1 diabetes centers on insulin administration to replace or supplement the body's own insulin with the goal of achieving euglycemia and preventing or minimizing complications." | ( Anisowicz, SK; Larson, NS; Lombardo, JL; Meyers, TM; Reeves, PT; Rogers, PL, 2023) |
| "To test, for the first time in latent autoimmune diabetes in adults (LADA), the effects of autoantigen-specific immunotherapy by intralymphatic administration of aluminium-formulated recombinant human glutamic acid decarboxylase 65 (GAD-alum); specifically, to test if this treatment is safe, to test whether it induces a strong immunological response akin to a similar protocol in type 1 diabetes and to look for associations with preserved beta-cell function." | ( Balasuriya, C; Björklund, A; Casas, R; Grill, V; Hals, IK; Ludvigsson, J, 2023) |
| "As in a similar protocol used in type 1 diabetes, treatment exerts a strong immunological impact and is compatible with protection of beta-cell function preferentially in HLA-DR3DQ2 LADA patients." | ( Balasuriya, C; Björklund, A; Casas, R; Grill, V; Hals, IK; Ludvigsson, J, 2023) |
| "Research in the treatment of type 1 diabetes has been addressed into two main areas: the development of "intelligent insulins" capable of auto-regulating their own levels according to glucose concentrations, or the exploitation of artificial intelligence (AI) and its learning capacity, to provide decision support systems to improve automated insulin therapy." | ( Baroni, MG; Cambuli, VM, 2023) |
| "Adults with type 1 diabetes mellitus (T1DM) or insulin- and/or secretagogue-treated type 2 diabetes mellitus (T2DM) were recruited from a probability-based internet panel." | ( Black, JE; Harris, SB; Kahkoska, AR; Klar, N; Ratzki-Leewing, A; Ryan, BL; Timcevska, K; Zou, G, 2023) |
| "Of the 147 participants (N = 50 type 1 diabetes, N = 94 type 2 diabetes/insulin-treated GDM) randomized to the CGM group of the GlucoMOMS trial, 115 participants had CGM metrics available and were included in the current study." | ( de Valk, HW; DeVries, JH; Evers, IM; Franx, A; Mol, BW; Painter, RC; Rademaker, D; Siegelaar, SE; van der Wel, AWT; van Eekelen, R; van Rijn, BB; Voormolen, DN, 2023) |
| "Treatment for type 1 diabetes (T1D) requires stimulation of functional β cell regeneration and survival under stress." | ( Do, JS; Filipowska, J; Hampton, R; Kondegowda, NG; Leon-Rivera, N; Levister, C; Levy, CJ; Li, R; Ogyaadu, S; Penninger, JM; Reijonen, H; Vasavada, RC, 2023) |
| "In patients with type 1 diabetes of recent onset, daily treatment with baricitinib over 48 weeks appeared to preserve β-cell function as estimated by the mixed-meal-stimulated mean C-peptide level." | ( Ahmed, S; Atlas, G; Cameron, FJ; Colman, PG; Couper, JJ; Doyle, ME; Gorelik, A; Hall, C; Harbison, JE; Harrison, LC; Kay, TWH; Krishnamurthy, B; Litwak, S; MacIsaac, RJ; Martin, FJ; Sanz-Villanueva, L; So, M; Thomas, HE; Trivedi, P; Waibel, M; Wentworth, JM, 2023) |